David Raben CV 1-13-16 PDF - University of Colorado Denver

David Raben CV 1-13-16 PDF - University of Colorado Denver

1/26/16 David Raben, MD Professor And Associate Scientist Marsico Endowed Chair in Head and Neck Cancer Research Department of Radiation Oncology University of Colorado Denver 1665 Aurora Court, Suite 1032 MSF706 Aurora, CO 80045 P: 720-­‐‑848-­‐‑0116 / F: 720-­‐‑848-­‐‑0238 David.Raben@ucdenver.edu Date of Birth: Place of birth: Citizen of: June 6, 1963 New York, New York United States Postgraduate Education 1995 Diplomat – American Board of Radiology Certification Examination (Radiation Oncology) Postgraduate Education 1993 – 1994 Chief Resident, Radiation Oncology. The Johns Hopkins Hospital – Baltimore, MD 1991 – 1993 Resident, Radiation Oncology. The Johns Hopkins Hospital – Baltimore, MD 1990 – 1991 Transitional Year. University of Hawaii Medical School – Honolulu, HI Undergraduate/Graduate Education 1985 – 1990 The Bowman Gray School of Medicine – Wake Forest University, Winston Salem, NC (M.D.) 1981 – 1985 Duke University – Durham, NC (B.A.) Current Academic Appointments 2007 Professor, Department of Radiation Oncology. University of Colorado Denver 2001 – 2007 Associate Professor, Department of Radiation Oncology. University of Colorado Denver 1998 – 2001 Assistant Professor, Department of Radiation Oncology. University of Colorado Denver Previous Academic Appointments 1994 -­‐‑1998 Assistant Professor and Associate Scientist, University of Alabama Comprehensive Cancer Center Current Hospital and Professional Appointments 1998 1998 1998 Staff Privileges. University of Colorado Hospital – Aurora, CO Staff Privileges. Denver Health Medical Center – Denver, CO Consulting Privileges. Denver Veterans Administration Medical Center – Denver, CO Previous Hospital and Professional Appointments 1996 – 1998 Residency Program Director, Department of Radiation Oncology. University of Alabama -­‐‑ Birmingham, AB 1994 – 1998 Consulting Privileges. Veterans Administration Medical Center – Birmingham, AB Medical Licensure: Colorado, 1998-­‐‑ #37178 (current) Alabama, 1994-­‐‑1998 (expired) Awards and Honors 2015 Selected for the American Society of Clinical Oncology Ambassador Program for Multidisciplinary Cancer Management Courses 2014 Selected as one of 30 faculty to participate in Univ. of Colorado CCTSI Leadership in Team Science Program (LITeS) 2009 Honored by Cancer League of Colorado for contributions in cancer research 2006 Elected University of Colorado School of Medicine Faculty Senate Secretary 2003 Outstanding Teacher Award. University of Colorado Denver 2001 SPORE Career Development Award. Tobacco Related Malignancies Program. University of Colorado Denver 1999 Invited participant. Gordon Research Conference. Ventura, CA 1997 Travel Grant Award. European Society for Therapeutic Radiology and Oncology 1996 Invited participant. Methods in Clinical Cancer Research Workshop. Vail, C O 1995 Invited participant. Molecular Biology in Clinical Oncology Workshop. Aspen, CO 1990 C. B. Dean Memorial Award for Outstanding Performances in Clinical Oncology. The Bowman Gray School of Medicine 1988 Summer Research Fellowship. National Institutes of Health 1987 First Place –Student Research Presentations. The Bowman Gray School of Medicine 1987 Alpha Omega Alpha Research Fellowship 1987 Student Research Assistant Award. Professional Oncology Education Program. The Bowman Gray School of Medicine Current Major Professional Memberships 2013 Developmental Therapeutics Committee (NRG Oncology) 2012 Lung Cancer and Lung Cancer Working Group Committee (SWOG) 2006 The American Head and Neck Cancer Society (AHNS) 2005 The International Association for the Study of Lung Cancer (IASLC) 2001 American Association of Cancer Research (AACR) 1998 American Society of Clinical Oncology (ASCO) 1998 American College of Radiology (ACR) 1995 American Society of Radiation Oncology (ASTRO) Current Professional Activities • ASCO Ambassador Multidisciplinary Cancer Management Courses • ASTRO Abstract Reviewer: Head and Neck Cancer • Reviewer for Italian Association for Cancer Research •
•
•
•
Leadership for Innovative Team Science (LITeS) Program through CCTSI NCI Head and Neck Cancer Steering Committee, Immunotherapy Task Force ASCO/IAEA Cancer Division of Programme of Action for Cancer Therapy Lung, Head and Neck T32 Training Grant Committee •
•
•
•
•
•
•
•
•
Past Chair, Planning Committee, ASTRO/ASCO Head and Neck Cancer Symposium, AZ Developmental Therapeutics Committee Co-­‐‑Chair (RTOG/NRG) University of Colorado School of Medicine Admissions Executive Committee IASLC Program Comm. For 2015 International Lung Cancer Symposium, Denver CO University of Colorado Cancer Committee Southwest Oncology Group Radiation Oncology Committee NCCN Guidelines for Prostate Cancer Committee Foundations of Doctoring Program for First Year Medical Students Problem Based Learning Substitute Teaching Member Past Professional Activities 2013 Chair, ASTRO/ASCO Head and Neck Cancer Symposium, 2012 University of Colorado Denver Clinical Strategic Task Force Committee 2012 Chair-­‐‑Elect, ASTRO/ASCO Head and Neck Cancer Symposium 2009 Program Committee: 2nd ASTRO/ASCO Head and Neck Cancer Symposium, Scottsdale AZ 2009 GU Radiation Oncology Sub-­‐‑Committee Chair, SWOG 2009 University of Colorado School of Medicine PBL “Molecules to Medicine” Lectures 2008 Program Chair: ASTRO Presidential Symposium on Targeted Therapies in Cancer, Boston MA 2007 Head and Neck Cancer Steering committee, Radiation Therapy Oncology Group 2007 Program Director Co-­‐‑Chair, ASTRO/ASCO Head & Neck Cancer Symposium, Palm Springs CA 2006 Moderator – ASTRO Presidential Symposium on HNC, Session IV 2005 Director-­‐‑ Radiological Sciences Core for UCCC 2005 UCH Hospital Credentialing Committee 2005 Education Committee, American Society of Therapeutic Radiology and Oncology 2005 Lung Cancer Program Planning Committee, American Society of Clinical Oncology 2005 Co-­‐‑Moderator, Head and Neck Poster Discussion Session, 47th Meeting of the American Society of Therapeutic Radiology and Oncology, Denver, CO 2004 American Society of Clinical Oncology Publications Committee 2004 American Society of Therapeutic Radiology and Oncology Steering Committee on Promoting Research 2002 American Society of Therapeutic Radiology and Oncology Translational Research Committe e 2002 The Scientific Advisory Board of the Cancer League of Colorado (CLC) 2002 American Society of Clinical Oncology – Program Committee Member – Department of Education, Science & Publications 2002 UCCC Hormone Related Malignancies Search Committee 2002 UCHSC -­‐‑-­‐‑ Cancer Investigations Core Search Committee 2002 UCCC K-­‐‑12 Mentor for Dr. Elaine Weng – Radiation Oncology 2001 UCHSC Medical School Admissions Committee 2001 University of Colorado Comprehensive Cancer Center, Gastrointestinal Tumor Working Group 2000 ASTRO Refresher Course Committee 2000 ASTRO Young Leadership Committee 2000 UCHSC Medical School Advisory Committee 1999 American College of Radiology Committee Standards For Radiation Oncology, Anal/Rectal Cancer Panel 1998 Medical Student Mentorship Program, University of Colorado Health Science Center (UCHSC) 1998 Gastrointestinal Steering Committee, Radiation Therapy Oncology Group (RTOG) 1998 Co-­‐‑Section Head, Head/Neck Tumor Working Group, University of Colorado Health Sciences Center 1997-­‐‑1998 Medical Student Mentorship Program, University of Alabama at Birmingham 1996-­‐‑1997 1996-­‐‑1998 National Comprehensive Cancer Network Expert Panel on Unknown Primary Cancer, University of Alabama at Birmingham Cancer Center Representative Section Head – Gastrointestinal Working Group, University of Alabama at Birmingham, Comprehensive Cancer Center Ad Hoc Reviewer 2015 ASCO Educational Book 2014 ASCO Educational Book 2013 Cancer Research 2011 Clinical Genitourinary Cancer 2011 Radiation Oncology 2005 Molecular Cancer Therapeutics 2005 Head and Neck 2004 British Journal of Cancer 2003 International Journal of Radiation Oncology Biology Physics 2002 Clinical Cancer Research 1997 Journal Clinical Oncology Editorial Boards 2005-­‐‑2006 International Journal of Cancer 2011-­‐‑2014 Head and Neck 2014 -­‐‑ Clinical Genitourinary Cancer Invited Local/National/International Presentations and Visiting Professorships 2015 “Getting Out Of The Box: Managing Head and Neck cancer for the Next 5 Years” Princess Margaret Hospital Grand Rounds, December, 2015 2015 “Inhibiting DNA Repair and Immune Suppression in Head and Neck Cancer”, University of Miami Cancer Grand Rounds, November, 2015 2015 “Decision-­‐‑Making in Early Stage Prostate Cancer”, Rocky Mountain Cancer Conference, Univ. of Colorado, November, 2015 2015 “Management of Head and Neck Cancer”, ASCO MCMC Program, Zimbabwe, September, 2015 2015 “Role of Radiotherapy in Rectal Cancer”, ASCO MCMC Program, Zimbabwe, September, 2015 2015 “Why, when and how should oncologists work together as a multidisciplinary team?” ASCO MCMC Program, Zimbabwe, September, 2015 2014 “Best of the Multidisciplinary Head and Neck Symposium” 2014 ASCO Annual Meeting. Chicago, IL. May 2014 “Molecular, Immunologic and Radiation Strategies For High Risk Prostate Cancer : What’s On The Horizon?” 15th Annual Sun Sand and Seeds Conference. Boca Raton, FL. March 2014 “The Modular Road to Defining and Targeting High-­‐‑Risk Head and Neck Patients” 2014 Multidisciplinary Head and Neck Cancer Symposium. Scotsdale, AZ. February 2014 “Oropharynx Cancer and Try Our RoboticS (TORS)” ACRO Annual Meeting. Orlando, FL. February 2013 “Head and Neck Cancer and our Future” Moffitt Cancer Center Grand Rounds. Tampa, FL. December 2013 “Opportunities for Radiation and DNA Repair Inhibition – Stopping the Mario Brothers” UNC Visiting Professor. Chapel Hill, NC. October 2013 “DNA Repair Inhibition and HNC… and other stuff” Visiting Professor Resident Lecture MD Anderson Cancer Center. Houston, TX. September 2013 “Management of P16 (-­‐‑) Head and Neck Cancer” Visiting Professor Lecture. Memorial Sloan-­‐‑ Kettering Cancer Center. New York, NY. May 2013 “Managing P16(-­‐‑) head and neck cancer: new avenues for success – without the added morbidity”. UC Davis Visiting Professor Lecture. Sacramento, CA. April 2013 “Randomized trials on EGFr targeting and biological modifiers” 4 th ICHNO Conference, 2013 2013 2012 2012 Barcelona, Spain. February “SBRT treatment of oligimetastate SCLC after chemotherapy” IASLC Lung Cancer Congress. Santa Monica, CA. February “Developmental Therapeutics” RTOG Spring Meeting. San Diego, CA. January “A Multidisciplinary approach to personalizing the treatment of head and neck cancers.” IMER Live Presentation. Baptist Hospital. Pensacola, FL. June “Biologics and Radiation for HNC in 2012 – What’s next on the horizon?” MCD, Boulder, CO, January 2012 2012 2012 2012 2011 2011 2011 2011 2011 2010 2010 2010 2010 2010 2010 2010 2009 2009 2009 2009 2009 2008 2008 2008 2008 2008 2008 2007 “Stereotactic Body Radio-­‐‑ablation in Head and Neck Cancer”, ASTRO Head and Neck Cancer Symposium, Scottsdale AZ, January “New Insight in DNA repair targeting and radiotherapy in head and neck cancer.” International Conference on Translational Research in Radiation Oncology. Geneva, Switzerland. February. “A Multidisciplinary approach to personalizing the treatment of head and neck cancers.” IMER Live Presentation. Walter Reed National Army Base. Bethesda, MD April. “If I was in Dallas and could treat head and neck cancer anyway I want in 2012…here is what I would do.” UTSouthwestern Visiting Professorship. Dallas, TX. April. 22nd LH Gray International Conference: Realizing the potential of drug/radiation interactions in cancer treatment. “Biological aspects of radiotherapy targets”. Manchester UK. February ASCO GU Symposium. “Best of Journals: Prostate Cancer. Orlando, FL. February International Symposium “Advances and Perspectives in Thoracic and Upper Aerodigestive Malignancies”. Athens, Greece. March ASCO Annual Meeting. “Integration of Targeted Therapy with Radiation”. Chicago, IL. June “Conventional and Biologic Management of HNC in 2012: What’s a Buckeye to do?” Ohio St. Grand Rounds. Columbus, Ohio, November “Management of Oropharynx Cancer – Case Presentations, 2nd ASTRO/ASCO Head and Neck cancer Symposium, February, Scottsdale, AZ, February “What Biologics and New Paradigms Should We Look at with Radiation Therapy to Improve Outcomes?” SWOG Translational Radiation Oncology Symposium, April. “Updates on the Management of Head and Neck Cancer in 2010” UCSF Grand Rounds, Radiation Oncology, April. “Radiation Combined Strategies in the Clinic” AstraZeneca MedImmune 2010 Cross Alliance Scientific Symposia. Alderley Park, Macclesfield UK. June Annual Community Oncology Research Forum, Dallas TX. August “New Insight in Molecular Targeting and Radiotherapy” ESTRO 29, Barcelona Spain. September. “Targeted Therapies and Radiation in Head and Neck Cancer: Picking the Next Winner” Mount Sinai Comprehensive Cancer Center Grand Rounds, Miami Beach FL. October. 9th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting. The Fairmont Miramar Hotel, Santa Monica, CA. Feb 18-­‐‑21, 2009 “Are We Radiation Therapists or Oncologists with Radiation Expertise? Visiting professor, Stanford Cancer Center, Radiation Oncology Rounds, Palo Alto CA 13th Annual World Congress of Lung Cancer Meeting. San Francisco, CA. July 3 1-­‐‑ Aug 4, 2009 Thyroid and Neoplasm’s Symposium. Denver, CO September 11, 2009. “Management of Head/Neck Cancer” – VA MC Grand Rounds. Denver CO. Dec 15, 2009 2008
“Targeted Therapies in HNC: EGFR inhibition worked, what’s the next step?”, Cancer Center Grand Rounds, University of Geneva, Geneva, Switzerland. “Targeted Therapies in HNC: EGFR inhibition worked, what’s the next step?”, CIOCC Oncologia Medica, Madrid, Spain “No Level I Evidence for Use of Induction Chemotherapy in HNC”, 44th Annual American Society of Clinical Oncology meeting, Chicago, Ill. “Targeted Therapies and Radiation : What lies beyond EGFR inhibition?”, 7th International Head and Neck Conference, San Francisco, CA “Updates on the UCCC Lung SPORE Program”, Semi-­‐‑annual RTOG meeting, Philadelphia, PA “Anti-­‐‑Angiogenics and Radiation in Lung Cancer”, 5th Annual Symposium Combined Modality Therapy, UT Southwestern, Dallas, TX. “Treatment Options For Head and Neck Cancer: Where are we and where are we going?, Visiting professor, KU Cancer Center Grand Rounds, Kansas City, Kansas “The Role of Targeted Agents and Radiation in Thyroid Cancer”, Endocrinology Grand Rounds, UCHSC, January 2007 2007 2007 2007 2007 2006 2006 2006 2006 2006 2006 2006 2006 2005 2005 2005 2005 2005 2004 2004 2004 2004 2004 2004 “The Evolving Role of Targeted Therapy and Radiation In Cancer Management” DUKE University Grand Rounds, Durham, NC February. ‘The Evolving Role of Targeted Therapy and Radiation in Cancer Management” OHSC Grand Rounds, Portland, OR February. “The Evolving Role of Targeted Therapy and Radiation in Cancer Management” South West Oncology/Hematology Clinic, San Antonio, TX March. “Targeted Therapies in HNC: Where are we headed next?”, Christies Hospital, Manchester, UK “Targeted Therapies in HNC: EGFR inhibition worked – what’s next?”, Institute Gustave Roussy, Radiation Oncology, Paris, France “Update on the toxicity and response of a Phase I study of Iressa and radiation or chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck”, ICTR meeting, Luganno, Switzerland, March. (CME) “Beyond EGFR Inhibition -­‐‑ what else is out there on the horizon for radiation oncology?” – University of Texas Southwestern Advances in Lung and HNC Symposium, March (CME) “Updates on the Management of Esophageal Cancer with Radiation in 2006” Vanderbilt University Department of Radiation Oncology residents didactic, Nashville, TN, July. “Using Biologics to Enhance Radiation in 2006” – Vanderbilt Basic Sciences Grand Rounds, Nashville, TN, July. (CME) “Clinical Issues with EGFR Inhibition and Radiation”: 2006 Translational Research in Radiation Oncology, Physics and Biology Symposium, Boston, MA. September (CME) “Small Molecule Tyrosine Kinase Inhibitors and Radiation-­‐‑ EGFR and Beyond” 2nd Annual Integration of Novel Biologic Therapies and Radiation, ASTRO, Philadelphia, PA. November. (CME) “Erbitux and Radiation in HNC” 2nd Rencontres Nationales Merck Oncologie, Cannes, France, December. “Novel Biologics and Radiation in NSCLC in 2006” – 6th Annual Targeted Therapies in NSCLC, Santa Monica, CA, January. (CME) “Anti-­‐‑Angiogenesis Inhibitors and Radiation in the Treatment of NSCLC-­‐‑ Where are we in 2005?” 5th Annual Targeted Therapies in NSCLC, Steamboat Springs, CO, February 12th. (CME) “Targeted Agents to Enhance Radiation in HNC and NSCLC-­‐‑ Pre-­‐‑clinical Studies”, Wake Forest University Cancer Center, April 13. (CME) “Overview of Targeted Agents to Enhance Radiation Therapy”, Johns Hopkins Hospital B i-­‐‑ annual Meeting, June 4. “New Targeted Agents to Enhance Radiation Effects: Where Are We in 2005?” University of Maryland, visiting professor, November. (CME) “New Targeted Agents to Enhance Radiation Effects in HNC: Where Are We in 2005?” Delaware Society of Clinical Oncology (DSCO), November. (CME) “ZD6474 and Radiation – Pre-­‐‑Clinical Studies”, Targeted Therapies in Radiation Meeting, Lake Tahoe, July 16-­‐‑18. CTEP Early Drug Development Fall Meeting – 1). “Review of EGFR Inhibitors and Radiation”; 2). “A Phase I Study of ZD1839 in Combination with Radiation and Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck.” Bethesda, Maryland. “Anti-­‐‑tumor efficacy of ZD6474, a VEGFR tyrosine kinase inhibitor with additional activity against EGFR tyrosine kinase, alone and in combination with radiotherapy in human head and neck cancer”. 3rd International Chicago Symposium on Malignancies of the Chest and Head and Neck, Chicago, Ill, “Targeted Therapies To Enhance Radiation Therapy – Where Are We in 2004?” University of Utah Huntsman Cancer Center – ENT Grand Rounds, Nov 5. (CME) “Targeted Therapies and Radiation in HNC – where are we in 2004?” – Mary Corwin Hospital Grand Rounds, Peublo, CO (CME) “Combining Targeted Therapies and Radiation in the Treatment of Head and Neck Cancer – Where are we in 2004?” – Mayo Clinic HNC Grand Rounds, Nov12. 2004 2003 2003 2003 2003 2003 2002 2002 2002 2001 2000 1999 1999 1998 1998 1998 1997 1996 “Review of Targeted Agents and radiation in Head and Neck Cancer – Challenges Ahead” – MD Anderson Cancer Biology Division, Dec 13. “Targeted Therapies in Lung Cancer”, Marbella, Spain Jan 15-­‐‑18 “Modulating Angiogenesis and EGFR To Enhance Radiation” 3rd Annual Roundtable Leader Symposium On Targeted Therapies In Lung Cancer, Aspen, CO, Feb. 5-­‐‑9th. “Modulating EGFR and Angiogenic Signaling To Enhance Radiation Response”-­‐‑-­‐‑MD Anderson Cancer Center, May 14. The Emerging Role of EGFR and COX-­‐‑2 Inhibitors in the Treatment of Human Cancers: Walk Before You Run! 12th International Conference of Radiation Research, Brisbane, Australia, August. Targeted Therapies Review – Post-­‐‑ASTRO Review Course, Washington University – St. Louis, December 5. “EGFR and VEGFR Modulation in NSCLC” -­‐‑-­‐‑Oncologia 2002 Il Futuro Oggi, Napoli Palazzo Reale, September 18-­‐‑21. “ZD6126, A Tumor Vascular Targeting Agent, Potentiates The Effects Of Radiation And ZD1839 In NSCLC” -­‐‑-­‐‑ASCO Molecular Targets Meeting, San Diego CA, Nov 8-­‐‑11. “EGFR and VEGFR Modulation To Enhance Radiation” -­‐‑-­‐‑ University of Indiana Radiation Oncology Annual Educational Meeting, Indianapolis, IN, Nov 16. “Therapeutic Strategies for Localized Prostate Cancer II” -­‐‑-­‐‑11th International Prostate Cancer Update, Vail, Colorado “Management of Head and Neck Cancer in the 21st Century” -­‐‑-­‐‑ Memorial Hospital, Colorado Springs, Colorado “Antagonists Against Growth Factor Receptors to Enhance Radiation Against NSCLC” -­‐‑-­‐‑ 6th IASLC Lung Tumor Biology Workshop, Aspen, Colorado “Antagonists Against Growth Factor Receptors to Enhance Radiation in the Treatment of NSCLS and Head and Neck Cancer” -­‐‑-­‐‑ 1st International Chicago Symposium on Malignancies of the Chest and Head and Neck , Chicago, Illinois “Pancreatic Cancer: Past, Present, Future” – Oncology Grand Rounds, University of Alabama Comprehensive Cancer Center “Radiation Standards and Innovations in Non-­‐‑Small Cell Lung Cancer” sponsored by the Institute for Continuing Healthcare Education – Birmingham, Alabama “Genetic Radio-­‐‑Isotope Targeting Strategies (GRITS) for Brain Tumors” – sponsored by the American Brain Tumor Association – Chicago, Illinois “Integration of Gene Therapy and Radiation Therapy” – Oncology Grand Rounds, University of Alabama at Birmingham Comprehensive Cancer Center “Strategies to Augment Cancer Radiotherapy Employing Gene Transfer Methods” Emergent Technologies for the Treatment of Brain Tumors – Lake Tahoe, California Leader – National/International Conferences 1.
Chair, 2014 Multidisciplinary Head and Neck Cancer Symposium. ASTRO/ASCO/American Head and Neck Cancer Society. Scottsdale, AZ 2014 2.
Chair-­‐‑elect, 2012 Multidisciplinary Head and Neck Cancer Symposium. ASTRO/ASCO/American Head and Neck Cancer Society. Phoenix, AZ 3.
Radiation Oncology Program Co-­‐‑Chair, 8th International Conference on Head & Neck Cancer, Toronto, 2012. 4.
Program Committee, 2010 Multidisciplinary Head and Neck Cancer Symposium. ASTRO/ASCO/ American Head and Neck Cancer Society. Scottsdale AZ 5.
Program Committee Co-­‐‑Chair, 2007 Multidisciplinary Head and Neck Cancer Symposium. ASTRO/ASCO/ American Head and Neck Cancer Society. Rancho Mirage, CA, Jan.18-­‐‑20. 6.
Organized Fourth Annual Roundtable Leader Consortium on Targeted Therapies For Head And Neck Cancer with Kian Ang, M.D, Ph.D, Miami FL, Feb 8-­‐‑11, 2006. 7.
Organized Third Annual Roundtable Leader Consortium on Targeted Therapies For Head And Neck Cancer with Kian Ang, M.D, Ph.D, Cancun, Feb 16-­‐‑20, 2005. 8.
Organized Second Annual Roundtable Leader Consortium on Targeted Therapies For Head And Neck Cancer with Kian Ang, M.D, Ph.D, Jamaica, Feb 25-­‐‑29, 2004 9.
Organized First Annual Roundtable Leader Consortium on Targeted Therapies For Head And Neck Cancer with Kian Ang, M.D, Ph.D, Puerto Rico Feb 5-­‐‑9, 2003. Didactic Lectures and Teaching Records at the University of Colorado D enver 2015 “Salivary Gland Cancers” – Radiation Oncology Residents 2014 “LDR Brachytherapy for Prostate Cancer” – Radiation Oncology Residents 2014 “Management of Bladder Cancer 2014” – Radiation Oncology Residents 2013 “Thyroid Cancer” – Radiation Oncology Resident Lecture 2013 “Prostate Cancer” – Radiation Oncology Resident Lecture 2012 “Conventional and Biologic Management of HNC in 2012” University of Colorado cancer Center Symposium Series, February 2012 “Prostate Cancer” – Radiation Oncology resident teaching didactic. August 2011 “Pancreas Cancer – what’s a Radiation Oncologist to do?” Surgery Grand Rounds, UCD. April 2011 “Intermediate Prostate Cancer” – Radiation Oncology Residency Teaching Didactic. August 2010 “Management of Nasopharyngeal Cancer” – Radiation Oncology resident Lecture 2009 “Prostate Cancer” – Radiation Oncology residency teaching didactic. September 2009 “Prostate Cancer” – Medical Oncology Grand Rounds. September 2009 “Head and Neck Cancer in Radiation Oncology” – Dermatology Grand Rounds. October 2009 “ENT Research Day” –Guest Speaker, UCD Campus. June 2009 PBL Tutor Sessions for Medical Students (6 sessions between September – March 2010) 2009 “Thyroid Neoplasm Symposium” UCD Campus – September 2009 “Prostate Cancer for VA Patients” VAMC Resident Lecture – December 2008 “Unknown Primary of Head and Neck Cancer” – Radiation Oncology residency teaching didactic. April 2008 Surgery Grand Rounds UCD. May 2008 “Pancreas Cancer” – Radiation Oncology residency teaching didactic. May 2008 UCD Cancer Center Symposium. May 2007 “Deal or No Deal – Radiation and Targeted Therapy” –ENT UCHSC Grand Rounds. March 2006 “Bladder Cancer management in 2006 – a Radiation Oncology Perspective” – UCHSC Urology Grand Rounds, July. 2006 “New Targeted Agents to Enhance Radiation in 2006” – Pediatric Cancer Grand Rounds, August. 2006 “Advances in HNC – Update in Management in 2006” – Radiation therapy nursing seminar, October. (CME) 2006 “Cancer of Unknown Primary” -­‐‑ Radiation Oncology residency teaching didactic 2006 “Oropharynx Cancer Update” -­‐‑ Radiation Oncology residency teaching didactic 2006 “Management of Esophageal Cancer in 2006” -­‐‑ UCHSC Surgery Grand Rounds. December 2005 “Locally Advanced Prostate Cancer in 2005” – Radiation Oncology resident teaching didactic 2005 “Radiation Therapy for Skin cancer in the 21st Century” – Dermatology Grand Rounds -­‐‑ December 2005 “Radiobiology for Dummies” – Radiation Oncology residency teaching didactic 2003 “From Basics to Novel Therapies in HNC” -­‐‑ Medical Oncology Basic seminar series 2002 2001 2000 1999 1999 1999 1999 1998 1998 “Interfering With Growth Factor and Angiogenic Signaling To Enhance Radiation Therapy: A Preclinical and Clinical Review” – Medical Oncology Basic Seminar series “EGFR Modulation for Radiosensitization” – Dermatology Department Grand Rounds, UCHSC, November. “Pancreatic Cancer Management” -­‐‑Medical Oncology Basic Seminar Series, UCHSC “Radiation Biology”, -­‐‑-­‐‑Surgery Grand Rounds, UCHSC Invited Speaker, “Pancreatic Cancer,” -­‐‑ Medical Oncology Basic Research Conference, UCHSC “Management of NSCLC, A Radiation Oncology Perspective,” -­‐‑-­‐‑ Lung Cancer Working Group, UCHSC “Cholangiocarcinoma: Controversies in Management and Future Therapies” – GI Grand Rounds, UCHSC “The 90’s Management to Head and Neck Cancer,” – UCCC Grand Rounds “Pancreatic Cancer: Past, Present, Future”, Surgery Grand Rounds, UCHSC Sabbatical Activities 2001-­‐‑2002 6 month sabbatical in Naples, Italy at the University of Naples that focused on combinations of biologics (EGFR and angiogenic inhibitors) and radiation in lung, pancreas, brain and HNC at the University of Naples in collaboration with Fortunato Ciardiello, M.D., Ph.D. and Giampaolo Tortora, M.D., Ph.D.; resulted in multiple publications in peer reviewed journals and ongoing collaborations between the University of Naples and UCCC. Organized with AstraZeneca and Dr. Gail Eckhardt a sponsored Italian Cancer fellowship at the University of Colorado with following mentees: •
Teresa Troiani, M.D. – 2005-­‐‑2006 •
Maria Pia Morelli, M.D. 2006 -­‐‑2007 8/2007-­‐‑3/2008 6 month sabbatical in Manchester, England. Consultant for Astra Zeneca, organized radiation biology seminar series for oncology division of AZ, developed radiation clinical trials with emerging product teams with novel therapeutics including DNA repair inhibition, initiated pre-­‐‑clinical studies; visiting professor and lecturer, Christie’s Hospital Cancer Center; performed re-­‐‑clinical research at the Patterson Institute with Dr. Ian Stratford evaluating Src kinase inhibition with radiation. Lead to initiation of Phase I trial of PARP inhibition with radiation and anti-­‐‑EGFR therapy for locally advanced head and neck cancer. Medical Student Research Mentorship: 2014 Whitney Summers: Head and Neck cancer database update and analysis 2014 Samuel Tesfalidet: Parp inhibition in head and neck cancer, summer research fellowship Co-­‐‑ mentor: XiaoJing Wang, M.D., Ph.D. 2013 Tyler Robin, M .D., Ph.D: Impact of submandibular sparing in HNC (Resulted in recent publication in Head and Neck) Grants Funded/Completed Funded/Pending: 2015 NIH/NCI SBIR Solicitation No. 2014-­‐‑01 Phase II grant: Development of Radiation Modulators during Radiotherapy Total Costs: $1,500,000 – 11/1/15 – 10/31/17 PI: James Crapo, MD, PhD Co-­‐‑PI: David Raben, MD 2015 A novel strategy to target hypoxic cells in prostate tumor Colorado Clinical and Translational Science Institute Direct costs: $30,000 01/01/15 -­‐‑ 06/30/15 PI: Gagan Deep Co-­‐‑PI: David Raben, M.D. 2014 Southwest Early Clinical Trials Consortium (SECT) UM1CA186688 Direct costs: $248, 049 03/14/14 – 02/28/19 Colorado PI: Gail Eckhardt, M.D. Co-­‐‑PI: David Raben, M.D. 2014 NIH/NCI NRG (Contact PI: Wolmark) U01CA180868 NRG Oncology Network Group Operations Center $39,771,934 3/1/14 – 2/28/19 0.60 “NRG Oncology’s primary mission is to improve the lives of adults with cancer by conducting multi-­‐‑institutional clinical and translational research trials in seven cancer disease sites that will define new standards of care, identify and verify useful biomarkers and biomarker-­‐‑based clinical decision-­‐‑making, create better risk stratification models, identify under-­‐‑ and over-­‐‑ treatment scenarios, and create new knowledge leading to greater opportunities for cancer survivorship.” Co-­‐‑Chair, Developmental Therapeutics: David Raben, M .D., Carol Aghajan, M .D., Samuel Jacobs, M.D. 2014 T32CA174648-­‐‑01 Training in Translational Research of Lung, Head and Neck Cancer Direct costs: $412,600 04/01/2013 – 03/31/2018 Clinical Mentor Completed: 2009 Hif-­‐‑1alpha in Head and Neck Cancer Radiotherapy Radiation Therapeutics and Biology Study Section, NIH R01 Total Costs: $250,000/year direct cost PI: Chuan Li, Ph.D. Co-­‐‑PI: David Raben, M .D. (5% effort) 4/1/2009 – 3/31/2014 2007 In Vivo Screen For Radiation Sensitizers Radiation Therapeutics and Biology Study Section, NIH 1 R21 DE017494-­‐‑01A1 Total Costs: $381, 817 PI: Tin Tin Su, Ph.D. Co-­‐‑PI: David Raben, M.D. (10% effort) Score: 166 2007 Evaluation of Nitric Oxide as a Radiosensitizer in NSCLC SPORE Competing Renewal Principle Project #5 Career development Award Total Costs: ~$50,000 annual PI: Chuan Li, Ph.D. Co-­‐‑PI – David Raben, M.D. (5% effort) 5/01/08-­‐‑4/30/2013 2006 Cs-­‐‑137 Irradiator for New Fitzsimons Campus Radiation Therapeutics and Biology Study Section, NIH 1 S10 RR022466-­‐‑01A1 Total Costs: $226,060 PI: David Raben, M.D. 2006 Predicting NSCLC and HNSCC Sensitivity to ZD6474 and ZD1839 by Microarray Analysis AstraZeneca pre-­‐‑clinical research grant Total costs: $33,005 PI: Barbara Frederick, Ph.D. (funded) Co-­‐‑PI: David Raben, M.D. (10% effort) 2006 Predicting NSCLC and HNSCC Sensitivity to AZD0530 by Microarray Analysis AstraZeneca pre-­‐‑clinical research grant Total costs: $44, 534 PI: Barbara Frederick, Ph.D. (funded) Co-­‐‑PI: David Raben, M.D. (5% effort 2005 Microarray Analysis to Predict ZD6474 and ZD1839 Response to Radiation RTOG seed grant Total costs: $15,000 PI: Barbara Frederick, Ph.D. (funded) Co-­‐‑PI: David Raben, M.D. (5% effort) 2005 In Vivo Screen For Radiosensitizers in Head and Neck Cancer NIH Exploratory/Developmental Research Grant Award (R21) Total costs: $381, 817 PI: Tin Tin Su. Ph.D. Co-­‐‑PI: David Raben, M.D. – 5% effort (resubmitted) Predicting Tumor Progression and Drug Sensitvity by CpG Methylation and M ALDI-­‐‑TOF (R21/R33) Total Costs: $300,000 – 7/1/2006 – 6/30/09 PI: Barbara Frederick, Ph.D. Co-­‐‑PI: David Raben, M.D. – 5% effort (under revision) 2005 2005 A Rapid Screen For Novel Cancer Therapeutics That Synergize With Radiation On Lung Cancer Xenografts UCHSC SPORE (Lung) Pilot Grant Total Costs: $35,000 PI: Tin Tin Su, Ph.D. Co-­‐‑PI: David Raben, M.D. – 5% effort (funded) 2003 Department of Health and Human Services Public Health Services – Telephone Counseling for Head and Neck Cancer – Reducing Barriers To Symptom Management and Palliative Care (R21) Total Costs: $320,000 – 7/1/05 – 6/30/07. PI: Kristen Kilbourn Co-­‐‑Investigator: David Raben, M.D. – 5% effort (funded) Grants Under Development 2016 Dual Targeting of PARP and EGFR in HNSCC 1R01CA181311-­‐‑01 Total costs: $250,000/year direct costs PI: David Raben, M.D. Co PI: Xiao Jing Wang, Ph.D. Submitted February 1, 2013 (re-­‐‑submission planned for June, 2015) Manuscripts Published 1.
Kucera LS, Raben D , Iyer N, Ricardo MI. Herpes Simplex Virus Type II Infection of Unstimulated Human T-­‐‑lymphocytes. Viral Immunol 2:11-­‐‑16, 1989. 2.
Benveniste RE, Raben D, Hill RW, Knott WB, Drummond JE, Arthur LO, Jahrling PB, Morton WR, Henderson LE, Heidecker G. Molecular Characterization and Comparison of SIV Isolates from Macaques, Mangabeys and African Green Monkeys. J Med Primatial 18:287-­‐‑303, 1989. 3.
Kucera LS, Leak EV, Raben D, Iyer N, Heise E. Herpes Virus Activation of HIV-­‐‑2 in Human T-­‐‑ lymphocytes. Aids Research and Human Retrovirus 6(5):641-­‐‑647, 1990. 4.
Raben D , Williams J, Abrams RA. The Clinical use of Multimodality Therapy in the Management of Cancer. In Vivo 8:635-­‐‑642, 1994 5.
Raben D , Buchsbaum DJ, Khazaeli MB, Rosenfeld ME, Gillespie GY, Grizzle WE, Liu T, Curiel DT. Enhancement of Radiolabeled Antibody Binding and Tumor Localization through Adenoviral Transduction of the Human Carcinoembryonic Antigen Gene. Gene Therapy 3:567-­‐‑580, 1996. 6.
Buchsbaum, DJ, Raben D, Stackhouse MA, Khazaeli MB, Rogers BE, Rosenfeld ME, Liu T, Curiel DT. Approaches to Enhance Cancer Radiotherapy Employing Gene Transfer Methods. Gene Therapy 3:1042-­‐‑68, 1996. 7.
Vickers SM, Rosenfeld M, Raben D, Sampson L. In Vitro Molecular Chemotherapy for Pancreatic Cancer. Hep Biliary Assoc. Volume II:1163-­‐‑1167, 1996. 8.
Rosenfeld ME, Vickers SM, Raben D , Wang M, Sampson L, Feng M, Jaffe E, Curiel DT. Pancreatic Carcinoma Cell Killing via Adenoviral Mediated Delivery of the Herpes Simplex Virus Thymidine Kinase Gene. Annals of Surgery, 225(5):609-­‐‑618, 1997. 9.
Rosenfeld ME, Rogers BE, Khazaeli MB, Mikheeva G, Raben D , Liu T, Curiel DT, Buchsbaum DJ. Adenoviral Mediated Delivery of Gastrin Releasing Peptide Receptor Results in Specific Tumor Localization of a Bombesin Analogue In Vivo. Clinical Cancer Research 3:1187-­‐‑1194, 1997. 10.
Miller R, Buchsbaum D, Reynolds P, Douglas J, Gilespie G, Mayo M, Raben D , Curiel D. Differential Susceptibility of Primary and Established Human Glioma Cells to Adenovirus Infection: Targeting Via the Epidermal Growth Factor Receptor Achieves Fiber Receptor-­‐‑Independent Gene Transfer. Cancer Research, 58, 5738-­‐‑5748. December 15, 1998. 11.
Robert F, Raben D, Spencer S. UFT/oral Calcium Folinate plus Radiation in Pancreatic Cancer. Oncology (Huntingt) Jul; 13(7Suppl 3):127-­‐‑8, 1999. 12.
Tincher SA, Kim RY, Ezekiel MP, Zinsli T, Fiveash J, Raben D, Bueschen JB, Urban DA. Effects of Pelvic Rotation and Needle Angle on Pubic Arch Interference during Transperineal Prostate Implants. Int. J. Radiation Oncology Biol. Phys., Vol. 4 7, No. 2, pp-­‐‑361-­‐‑363, May 2000. 13.
Childs H, Spencer SA, Raben D , Bonner JA, Newsome J, Robert F. A Phase I study of Combined UFT Plus Leucovorin and Radiotherapy for Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2000 Jul 1; 47(4):939-­‐‑44. 14.
Childs H, Cole T, Falkenberg E, Smith TJ, Alonso JE, Stannard JP, Spencer SA, Fiveash J, Raben D , Bonner JA, Westfall AO, Kim RY: A Prospective Evaluation of the Timing of Post-­‐‑Operative Radiotherapy for Preventing Heterotopic Ossification Following Traumatic Acetabular Fractures. Int. J. Radiat Oncol Biol Phys. Jul 15; 47(5):1347-­‐‑52, 2000 15.
Saltz L, Raben D, et al, Rectal Cancer: Presentation with Metastatic and Locally Advanced Disease, American College of Radiology. American College of Radiology ACR Appropriateness Criteria ™, Radiology; 215 (suppl), 2000. 16.
Madhu J, Merrick S, Coia L, Minsky B, Bader J, Janjan N, Raben D ., et al, Anal Cancer, American College of Radiology. American College of Radiology ACR Appropriateness Criteria ™, Radiology; 215 (suppl), 2000. 17.
Tepper J, Bader J, Janjan N, Minsky B, Coia L, Madhu J, Merrick S, Raben D, et al, Locally Unresectable Rectal Cancer, American College of Radiology. American College of Radiology ACR Appropriateness Criteria ™, Radiology ;215 (suppl), 2000. 18.
Rich T, Ota D, Rosenthal S, Minsky B, Bader J, Coia L, Janjan N, Madhu J, Merrick G, Raben D, et al, Management of Resectable Rectal Cancer, American College of Radiology. American College of Radiology ACR Appropriateness Criteria ™, Radiology; 215 (suppl), 2000. 19.
Gibbs P, Robinson W, Pearlman N, Raben D, Walsh, P, Gonzalez R, Management of Primary Cutaneous Melanoma of the Head and Neck: The University of Colorado Experience and a Review of the Literature. Journal of Surgical Oncology; 77:179-­‐‑185, 2001. 20.
Raben, D , Helfrich B, Chan D, et al, ZD1839, a Selective Epidermal Growth factor Receptor Tyrosine Kinase Inhibitor, Alone and in Combination With Radiation and Chemotherapy as a New Therapeutic Strategy in Non-­‐‑Small Cell Lung Cancer. Seminars in Oncology, Vol. 29, No 1, Suppl 4 (February); pp37-­‐‑46, 2002. 21.
Raben D , Giampaolo T, Ciardiello F. EGFR-­‐‑targeted therapies as radiosensitizers: an exciting new partnership. Signal 3 (3): 20-­‐‑23, September 2002. 22.
Raben D , Bianco C, Helfrich B, Weng E, Tortora G, Ciardiello F, Harari P, Interference with Epidermal Growth Factor Receptor Signaling: Paradigm For Improving Radiation Response in Cancer Treatment. Expert Review of Anti-­‐‑Cancer Therapy; 2(4) 461-­‐‑471, 2002. 23.
Bianco C, Tortora G, Bianco R, Caputo R1, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, and Ciardiello F. Enhancement of Antitumor Activity of Ionizing Radiation by Combined Treatment with the Selective Epidermal Growth Factor Receptor-­‐‑Tyrosine Kinase Inhibitor ZD1839 (Iressa). Clinical Cancer Research, 8: 3250-­‐‑3258, 2002. 24.
Di Lorenzo G, Riccardo A, Ciardiello F, Raben D , Bianco C, et al., External beam radiotherapy in bone metastatic prostate cancer: impact on patients’ pain relief and quality of life. Oncology Reports., 10:399-­‐‑404, 2003. 25.
Raben D , Helfrich B, Ciardiello F, Bunn PA. Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know. Lung Cancer. Aug;41 Suppl 1:S15-­‐‑ 22, 2003. 26.
Okunieff P, Meyn RE, Teicher BA, Thomas CR Jr, Gaspar LE, Raben D, et al. Report from the Radiation Oncology Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2003. Am J Clin Oncol. Oct;26(5):522-­‐‑9, 2003. 27.
Raben D , Bianco C, Milas L, Ang KK. Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress? Semin Radiat Oncol. Apr;14(2):139-­‐‑52, 2004. 28.
Raben D , Helfrich B, Bunn PA Jr. Targeted therapies for non-­‐‑small-­‐‑cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective. Int J Radiat Oncol Biol Phys. 59(2 Suppl):27-­‐‑38, 2004. 29.
Raben D ., Helfrich B. Angiogenesis inhibitors– A rationale strategy for radiosensitization in the treatment of non-­‐‑small cell lung cancer? Clinical Lung Cancer Jul;6(1):48-­‐‑57, 2004 30.
Raben D , Chen C, Troiani T and Weng E. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-­‐‑TKIs) in the Treatment of Head and Neck Cancer – The Next Step. Signal Vol.5 (2) 2004. 31.
Raben D , Bianco C, Damiano V, et al. Antitumor Activity of ZD6126, a Novel Vascular-­‐‑Targeting Agent, is Enhanced When Combined With ZD1839 (gefitinib, Iressa™) an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-­‐‑TKI) and Potentiates the Effects of Radiation in a Human Non-­‐‑Small cell Lung Cancer (NSCLC) Xenograft Model. M ol Cancer Ther. 2004 Aug;3(8):977-­‐‑83. 32.
Song J, Chen C, Raben D. The Emerging Role of EGFR-­‐‑Targeted Therapies and Radiation in Cancer of the Head and Neck. Oncology (Huntingt). Dec;18(14):1757-­‐‑67; discussion 1767, 1771-­‐‑2, 1777, 2004. 33.
Gridelli C, Maione P, Ciardiello F, Rossi A and Raben D. Treatment of locally advanced non small cell lung cancer in the elderly. Curr Opin Oncol. Mar;17(2):130-­‐‑134, 2005. 34.
Raben D , Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA Jr. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-­‐‑805. 35.
Ding M, Newman F and Raben D. New radiation therapy techniques for the treatment of head and neck cancer. Otolaryngol Clin North Am.2005, Apr; 38(2), 371-­‐‑95 (Review) 36.
Damiano V, Melisi D, Bianco C, Raben D , et al., Cooperative Antitumor Effect of Multitargeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma. Clin Cancer Res. Aug;11(15):5639-­‐‑5644, 2005. 37.
Raben D and Ryan A. Vascular Targeting Agents With And Without Radiation Therapy In Lung Cancer. Clin Lung Cancer. 2005 Nov;7(3):175-­‐‑9. 38.
Frederick B, Gustafson D, Bianco C, Ciardiello F, Dimery I and Raben D. ZD6474, an Example of a Dual EGFR and VEGFR Inhibitor: Its Effects Alone and In Combination with Radiation Therapy – An Assessment of Pre-­‐‑Clinical and Clinical Investigations. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):33-­‐‑7. 39.
Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D , et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006;45(7):848 -­‐‑55. 40.
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB., Jones CU, Sur R, Raben D, et al. Cetuximab plus radiotherapy for patients with locally advanced head and neck cancer. N Engl J Med. 2006 Feb 9;354(6):567-­‐‑78. 41.
Ballonoff A, Chen C and Raben D. Current radiation therapy management issues in oral cavity cancer. Otolaryngol Clin North Am. 2006 Apr;39(2):365-­‐‑80. 42.
Rabinovitch R, Eldridge B, Berkey B, Raben D , Ang KK, Fu K. The impact of baseline nutritional support on treatment outcome in patients with locally advanced squamous cell cancer of the head and neck treated with definitive radiotherapy: report of the Radiation Therapy Oncology Group (RTOG) Trial 90-­‐‑03. Head Neck. 2006 Apr;28(4):287-­‐‑96. 43.
Lewis KD, Dollarhide S, Fitzpatrick JE, Gonzalez R, High WA, McCarter MD, Olsen C, Raben D. Metastatic malignant melanoma from an unknown primary presenting as a large axillary mass. Oncology (Williston Park). 2006 Jun; 20(7):763-­‐‑70. 44.
Kavanagh BD, Raben D . Toward a unified target theory in oncology. Future Oncol. 2006 Aug;2(4):435-­‐‑ 6. 45.
Rothschild B, Shim AH, Irb KB, Hea JA, Garcia M, Sacks PG, Frederick B, Raben D, and Weed SA. Cortactin Overexpression Regulates Arp2/3 Complex Activity, Motility and Invasion in Carcinomas with Chromosome 11q13 Amplification. Cancer Res. 2006 Aug 15;66(16):8017-­‐‑25. 46.
Schefter T, Kavanagh B, Raben D, et al. A phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases: Initial report of dose escalation and early toxicity. Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4 Suppl):S120-­‐‑7. 47.
Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, Pasqualetti F, Troiani T, Tacca MD, Raben D, et al. Synergistic antitumor activity of the multitargeted kinase inhibitor ZD6474 with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res. 2006 Dec 1;12(23):7099-­‐‑107. 48.
Helfrich B, Raben D , Chan D, et al. Antitumor activity of the EGFR tyrosine kinase inhibitor gefitinib (ZD1839, IRESSA™) in NSCLC cell lines and xenografts correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res. 2006 Dec 1;12(23):7117-­‐‑7125. 49.
Harari PM. Cohen RB, Raben D, et al. The 2007 Inaugural ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium. Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S1-­‐‑3. 50.
Willey CD, Murphy BA, Netterville JL, Burkey BB, Shyr Y, Shakhtour B, Kish B, Raben D, Chen C, Song JI, Kane MA, Cmelak AJ. A Phase II multi-­‐‑institutional trial of chemoradiation using weekly docetaxel and erythropoietin for high-­‐‑risk postoperative head and neck cancer patients. Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1323-­‐‑31. 51.
Frederick B, Hefrich B, Coldren C, Bunn P and Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-­‐‑small cell lung carcinoma. M ol Cancer Ther. 2007 Jun;6(6):1683-­‐‑91. 52.
Chen C, Kane M, Song J, Campana J, Raben A, Hu K, Harrison L, Quon H, Dancey J, Baron A, Said S, Eckhardt SG and Raben D . Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 25:4880-­‐‑4886, 2007 53.
Rusthoven K, Ballonoff A, Raben D and Chen C. Poor Prognosis in Patients with Stage I-­‐‑II Oral Tongue Squamous Cell Carcinoma. Cancer. 2007 Nov 26;112(2):345-­‐‑351. 54.
Chow L, Chen C and Raben D . EGFR inhibitors and Radiation in HNSCC. Current Cancer Therapy Reviews 2007 55.
Gustafson DL, Frederick B, Merz AL, Raben D . Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-­‐‑positive and EGFR-­‐‑null human head and neck tumor xenografts. Cancer Chemother Pharmacol. 2008 Feb;61(2):179-­‐‑88. 56.
M Ding, F Newman, L Gaspar, B Kavanagh, K Stuhr, Raben D, JS Li and C-­‐‑M Ma. A 4D treatment planning tool for the evaluation of motion effects on lung cancer treatments. Journal of Physics: Conference Series 102. (2008). 57.
Rusthoven K, Chen C, Raben D , Kavanagh B. Use of external beam radiotherapy is associated with reduced incidence of second primary head and neck cancer: a SEER database analysis. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):192-­‐‑8. 58.
Rusthoven K, Flaig T, Raben D and Kavanagh B. High Incidence of Lung Cancer After Non– Muscle-­‐‑Invasive Transitional Cell Carcinoma of the Bladder: Implications for Screening Trials. Clinical Lung Cancer. 2008 Mar; 9(2): 106-­‐‑11. 59.
Rusthoven K, Raben D, Chen C, et al. Effect of Radiation Techniques in Treatment of Oropharynx Cancer. Laryngoscope. 2008 Apr, 118(4): 635-­‐‑9. 60.
Argiris A, Karamouzis VM, Raben D and Ferris R. Head and Neck Cancer. Lancet (Review) 2008 May 17; 371(9625): 1695-­‐‑709. 61.
Ballonof A, Kavanagh B, McCarter M, Kane M, Pearlman N, Nash R, Shah R, Raben D and Schefter T. Preoperative capecitabine and accelerated intensity modulated radiotherapy in locally advanced rectal cancer, a Phase II trial. Am Jour of Clin Oncology 2008 June; 31(3); 264-­‐‑271. 62.
Ballonoff A, Raben D , Rusthoven KE, Bassetti M, Kane M, Song JI, Chen C. Outcomes of patients with n3 neck nodes treated with chemoradiation. Laryngoscope. 2008 Jun;118(6):995-­‐‑8. 63.
E Bradshaw-­‐‑Pierce, C Steinhauer, Raben D and D Gustafson. Pharmacokinetic-­‐‑directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma. M ol Cancer Ther. 2008 Sep;7(9):3006-­‐‑17. 64.
Rusthoven R, Raben D and Chen C. Improved survival in patients with stage III-­‐‑IV head and neck squamous cell carcinoma treated with radiotherapy as the primary local treatment modality. Int J Radiat Oncol Biol Phys. 2008 Oct 1; 72(2); 343-­‐‑50. 65.
Le, Q and Raben D . Integrating Biologically Targeted Therapy in Head and Neck Squamous Cell Carcinomas. Semin Radiat Oncol. 2009 Jan;19(1):53-­‐‑62. Review. 66.
Olsen C, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Steigmann S and Raben D. Results of a Phase I Trial of 12 Patients with Locally Advanced Pancreatic Carcinoma Combining Gefitinib, Paclitaxel and Three-­‐‑Dimensional Conformal: Report of Toxicity and Evaluation of Circulating K-­‐‑ras as a Potential Biomarker of Response to Therapy. Am J Clin Oncol 2009 Apr, 32(2): 115-­‐‑21. 67.
Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-­‐‑Garcia M, Bemis LT. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose and sequence-­‐‑dependent manner. BJU Int. 2009 Jun;103(12):1729-­‐‑37. 68.
Raben A, Rusthoven KE, Sarkar A, Glick A, Benge B, Jacobs D, Raben D . Favorable toxicity and biochemical control using real-­‐‑time inverse optimization techniques for prostate brachytherapy. Brachytherapy. 2009 Jul-­‐‑Sep; 8(3): 297-­‐‑303. 69.
Rusthoven KE, Raben D, Schneider C, Witt R, Sammons S, Raben A. Freedom from Local and Regional Failure of Contralateral Neck with Ipsilateral Neck Radiotherapy for Node-­‐‑Positive Tonsil Cancer: Results of a Prospective Management Approach. Int J Radiat Oncol Biol Phys. 2009 Aug 1; 74(5); 1365-­‐‑70. 70.
Brechbuhl HM, Min E, Kariya C, Frederick B, Raben D , Day BJ. Select cyclopentenone prostaglandins trigger glutathione efflux and the role of ABCG2 transport. Free Radic Biol Med. 2009 Sep 15;47(6):722-­‐‑30. 71.
Okunieff P, Kachnic LA, Constine LS, Fuller CD, Gaspar LE, hayes DF, Hooks J, Ling C, Meyskens FL Jr, Philip PA, Raben D, Smalley SR, Swanson GP, Teicher BA, Thomas CR Jr, Vikram B, Zelefsky M J, Baker LH. Report from Radiation Therapy Committee of the Southwest Oncology Group (SWOG): research objectives workshop 2008. Clin Cancer Res. 2009 Sept 15:15(18):5663-­‐‑70. 72.
McCammon R, Kavanagh B, Newell S, Newman F and Raben D. Toxicity assessment of pelvic Intensity-­‐‑Modulated Radiotherapy with A hypofractionated simultaneous integrated boost to the prostate for intermediate-­‐‑ and high-­‐‑risk localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2009 Oct 1, 75;2): 413-­‐‑20. 73.
Ammer AG, Kelley LC, Hayes KE, Evans JV, Lopez-­‐‑Skinner LA, Martin KH, Frederick B, Rothschild B, Raben D, Green TP and Weed S. The Src Inhibitor AZD0530 Suppresses Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function. J Canc Sci Ther. 2009 Nov 1(2): 052-­‐‑061 74.
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-­‐‑year survival data from a phase 3 randomised trial, and relation between cetuximab-­‐‑induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21-­‐‑8. Erratum in: Lancet Oncol. 2010 Jan;11(1):1 75.
Diot Q, Olsen C, Kavanagh B, Raben D , Miften M. Med Phys. Impact of anatomical interventions on the localization of post-­‐‑prostatectomy cancer patients. 2010 Feb;37(2):629-­‐‑37. 76.
Rusthoven KE, Raben D, Song JI, Kane M, Altoos TA, Chen C. Survival and Patterns of Relapse in Patients With Oral Tongue Cancer. J Oral Maxillofac Surg. 2010 Mar; 68(3); 584-­‐‑9. 77.
Chung CH, Raben D. p16 Expression as a predictive biomarker of hypoxic cell-­‐‑sensitizing agents in oropharyngeal cancer. J Clin Oncol. 2010 Sep 20;28(27):4103-­‐‑4. 78.
Pugh TJ, Chen C, Rabinovitch R, Eckhardt SG, Rusthoven K, Swing R and Raben D . A phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.. Int J Radiat Oncol Biol Phys. 2010 Oct 1;78 (2); 521-­‐‑6. 79.
Rusthoven KE, Feigenberg SJ, Raben D, et al., Initial Results of a Phase I Dose-­‐‑Escalation Trial of Concurrent and Maintenance Erlotinib and Reirradiation for Recurrent and N ew Primary Head-­‐‑ and-­‐‑Neck Cancer. Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1020-­‐‑5. 80.
Diot Q, Olsen C, Kavanagh B, Raben D , Miften M. Dosimetric effect of online image-­‐‑guided anatomical interventions for postprostatectomy cancer patients. 81.
Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011 April 8:6(1):34 82.
Kavanagh BD and Raben D. Back to the future: a proton pro/con. Oncology (Williston Park) 2011 Jun;25(7):657, 660, 662-­‐‑3. 83.
Gregoire V, Hamoir M, Chen C, Kane M, Kawecki A, Julka PK, Wang HM, Prasad S, D'Cruz AK, Radosevic-­‐‑Jelic L, Kumar RR, Korzeniowski S, Fijuth J, Machiels JP, Sellers MV, Tchakov I, Raben D. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: A phase II, randomized, double-­‐‑blind, placebo-­‐‑controlled study. Radiother Oncol. 2011 Jul;100(1):62-­‐‑9 84.
Edwards A, Gladstone M, Yoon P, Raben D , Frederick B, Su TT. Combinatorial effect of maytansinol and radiation in Drosophila and human cancer cells. Dis Model Mech. 2011 Jul-­‐‑Aug; 4(4):496-­‐‑503. 85.
Huang Q, Li F, Liu X, Li W, Shi W, Liu FF, O’Sullivan B, He AZ, Peng Y, Tan AC, Zhou L, Shen J, Han G, Wang XJ, Thorburn J, Thorburn A, Jimeno A, Raben D , Bedford JS, Li CY. Caspase 3-­‐‑mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med. 2011 Jul 3;17(7):860-­‐‑6 86.
Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE. Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells. Clin Cancer Res. 2011 Aug 1;17(15); 5016-­‐‑25. 87.
Amin NP, Miften M, Kavanagh BD, Raben D, Camidge DR, Thornton D, Rockford N, Gaspar LE. Impact of induction chemotherapy on estimated risk of radiation pneumonitis in small cell lung cancer. J Thorac Oncol. 2011 Sep:6(9); 1553-­‐‑62. 88.
Siddiqui F, Raben D, Lu JJ, Grecula JC, Lo SS, Huang Z, Mayr NA, Teh BS, Yao M. Emerging applications of stereotactic body radiation therapy for head and neck cancer. Expert Rev Anticancer Ther. 2011 Sep;11(9):1429-­‐‑36. 89.
Bowles DW, Reddy K, Wine T, Ree A, Raben D, Chen C, Jimeno A. Locoregional recurrence of an HPV-­‐‑positive squamous cell carcinoma of the head and neck. Oncology (Williston Park), 2011 Oct;25(11): 1042-­‐‑8 Review 90.
Oberley-­‐‑Deegan RE, Steffan JJ, Rove KO, Pate KM, Weaver MW, Spasojevic I, Frederick B, Raben D, Meacham RB, Crapo JD, Koul HK. The antioxidant, MnTE-­‐‑2-­‐‑PyP, prevents side-­‐‑effects incurred by prostate cancer irradiation. PLoS One. 2012;7(9):e44178. 91.
Gladstone M, Frederick B, Zhenf D, Edwards A, Y oon P, Stickel S, Delaney T, Chan DC, Raben D , Su TT. A translation inhibitor identified in a Drosophila enhances the effect of ionizing radiation and taxol in mammalian models of cancer. Dis Model Mech. 2012 May; 5(3):342-­‐‑50. 92.
Pugh TJ, Lee NY, Pacheco T, Raben D. Microcystic adnexal carcinoma of the face treated with radiation therapy: a case report and review of the literature. Head Neck. 2012 Jul;34(7):1045 -­‐‑50. 93.
Raben D , Bunn PA. Biologically targeted therapies plus chemotherapy plus radiotherapy in stage III non-­‐‑small-­‐‑cell lung cancer: a case of the Icarus syndrome? J Clin Oncol. 2012 Nov 10;30(32):3909-­‐‑12. 94.
Amin N, Reddy K, Westerly D, Raben D, DeWitt P, Chen C. Sparing the larynx and esophageal inlet expedites feeding tube removal in patients with stage III-­‐‑IV oropharyngeal squamous cell carcinoma treated with intensity-­‐‑modulated radiotherapy. Laryngoscope. 2012 Dec;122(12):2736-­‐‑42. 95.
Kilbourn K, Anderson D, Costenaro A, Lusczakoski K, Borrayo E, Raben D . Feasibility of EASE: A psychosocial program to improve symptom management in head and neck cancer patients. Supportive Care in Cancer. 2013 Jan; 21(1); 191-­‐‑200. 96.
Carlson J, Licitra L, Locati L, Raben D, Persson F, Stenman G. Salivary Gland Cancer. Am Soc Clin Oncol Educ Book. 2013;2013:257-­‐‑63. 97.
Han G, Bian L, Li F, Cotrim A, Wang D, Lu J, Deng Y, Bird G, Sowers A, Mitchell JB, Gutkind JS, Zhao R, Raben D, ten Dijke P, Refaeli Y, Zhang Q, Wang XJ. Preventive and therapeutic effects of Smad7 on radiation-­‐‑induced oral mucositis. Nat Med. 2013 Apr;19(4):421-­‐‑8. 98.
Keysar SB, Astling DP, Anderson RT, WVogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska M J, Le, PN, Eagles-­‐‑Soukup JR, Kabo, SL, Takimotot SM, Sehrt DB, Umpierrez A, Pittman MA, Macfadden SM, Helber RM, Peterson S, Hausman DF, Said S, Leem TH, Goddard J A, Aracroli JJ, Messersmith WA, Robinson WA, Hirsch FR, Varella-­‐‑Garcia M, Raben D, Wang XJ, Song JI, Tan A, Jimeno A. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. M ol Oncol. 2013 Aug;7(4):776-­‐‑90. 99.
Rusthoven CG, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, Kavanagh BD. The Prognostic Significance of Gleason Scores in Metastatic Prostate Cancer. Urol Oncol. 2014 Mar 11; S1078-­‐‑1439(14) 100.
Rusthoven CG, Carlson JA, Waxweiler TV, Raben D, Dewitt PE, Crawford ED, Maroni PD, Kavanagh BD. The impact of definitive local therapy for lymph node-­‐‑positive prostate cancer: a population-­‐‑based study. Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1064-­‐‑73. 101.
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-­‐‑Sang JM, Raben D, et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May;12(5):686-­‐‑718. 102.
Kim DW, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, Kavanagh BD, Nanda A, Kueplian P, Brindle J, Cooley S, Perkins A, Raben D, Xie XJ, Timmerman RD. Predictors of rectal tolerance observed in a dose-­‐‑escalated phase 1-­‐‑2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):509-­‐‑17 103.
Rusthoven CG, Waxweiler TV, DeWitt PE, Flaig TW, Raben D, Kavanagh BD. Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer. Urol Oncol. 2014 Aug 20. pii: S1078-­‐‑1439(14)00266-­‐‑X 104.
Blumenfeld P, Pfeffer RM, Symon Z, Den RB, Dicker AP, Raben D , Lawrence YR. The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress? Br J Cancer. 2014 Aug 12. 105.
Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D , Gillison ML, Jordan RC and Le Q-­‐‑T. p16 protein expression and human papillomavirus status as prognostic biomarkers of non-­‐‑oropharyngeal head and neck squamous cell carcinoma. J Clin Oncol 2014 Sept 29. pii: JCO.2013.54.5228 106.
Gregory GN, Eagles J, Keysar SB, Wang G, Glogowska M J, Altunbas C , Anderson RT, Le PN, Morton JJ, Frederick B, Raben D, Wang XJ, Jimeno A. Hedgehog signaling drives radioresistance and stroma-­‐‑driven tumor repopulation in head and neck squamous cancers. Cancer Res. 2014 Dec 1;74(23):7024-­‐‑36. doi: 10.1158/0008-­‐‑5472.CAN-­‐‑14-­‐‑1346. [Epub ahead of print] 107.
Amini A, McDermott JD, Gan G, Bhatia S, Sumner W, Fisher CM, Jimeno A, Bowles DW, Raben D , Karam SD. Stereotactic body radiotherapy as primary therapy for head and neck cancer in the elderly or patients with poor performance. Front Oncol. 2014 Oct 8;4:274. doi: 10.3389/fonc.2014.00274. eCollection 2014. 108.
Papadimitrakopoulou VA1, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR, Jimeno A, Nedzi L,Vasselli JR, Lowe ES, Raben D. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. 2014 Oct 29. doi: 10.1002/hed.23922. [Epub ahead of print] 109.
Robin TP, Gan G, Tam M, Westerly D, Riaz N, Karam S, Lee N, Raben D. A Multicenter Review of Contralateral Submandibular Gland Sparing in Locally Advanced Oropharyngeal Cancers: Is it Safe? Head Neck. 2014 Dec 6. doi: 10.1002/hed.23928 [Epub ahead of print] 110.
Reddy K, Strom T, Plimpton R, Kavanagh BD, Petersen J, Wilson S, Maroni P, Raben D. Efficacy of pelvic intensity-­‐‑modulated radiotherapy with hypofractionated simultaneous integrated boost to the prostate for intermediate-­‐‑ and high-­‐‑risk prostate cancer. J Radiat Oncol (2014) 3:401–407. 111.
Dan TD, Raben D, Schneider CJ, Hockstein NJ, Witt RI, Dzeda M, Cormier JF, Raben A. Freedom from local and regional failure of contralateral neck with ipsilateral neck radiotherapy for node-­‐‑ positive tonsil cancer: Updated results of a prospective management approach. Oral Oncol. 2015 Jun;51(6):616-­‐‑21. 112.
Amini A, Westerly D, Waxweiler T, Ryan N, Raben D . Dose Painting to Treat Single Lobe Prostate Cancer Using Targeted External Beam Radiation Therapy Med Dosim. 2015 Autumn;40(3):256-­‐‑
61. 113.
Wozniak A, M oon J, Thomas CR, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara D, A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-­‐‑704865) in Patients with Inoperable Locally Advanced Stage III Non-­‐‑Small Cell Lung Cancer: SWOG S0533. Clin Lung Cancer. 2015 Sep;16(5):340-­‐‑7. 114.
Stickel S, Gomes N, Frederick B, Raben D , Su TT. Bouvardin Is A Radiation Modulator With A Novel Mechanism Of Action Radiat Res. 2015 Oct;184(4):392-­‐‑403. doi: 10.1667/RR14068.1. Epub 2015 Sep 28. 115.
Galloway TJ , Wirth L, Colevas AD, Gilbert J; Bauman JE; Saba NF; Raben D ; Mehra R; Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase 1 Study of CUDC-­‐‑101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-­‐‑73. 116.
Yom SS, Diehn M , Raben D . Molecular determinants of radiation response in non-­‐‑small cell lung cancer. Semin Radiat Oncol. 2015 Apr;25(2):67-­‐‑77. doi: 10.1016/j.semradonc.2014.12.007. Epub 2014 Dec 19. Review. 117.
Amini A, Jones B, Jackson MW, Yeh N, Waxweiler TV, Maroni P, Kavanagh BD, Raben D. Survival Outcomes of Dose-­‐‑Escalated External Beam Radiotherapy (DE-­‐‑EBRT) Versus Combined Brachytherapy for Intermediate-­‐‑ and High-­‐‑Risk Prostate Cancer Using the National Cancer Data Base.J Urol. 2015 Nov 11. pii: S0022-­‐‑5347(15)05217-­‐‑9. doi: 10.1016/j.juro.2015.11.005. [Epub ahead of print] 118.
Kessler ER, Amini A, Wilson SS, Anp-­‐‑C KB, Raben D, La Rosa FG, Crawford ED. Lymphoepithelioma-­‐‑Like Carcinoma of the Urinary Bladder. Oncology (Williston Park). 2015 Jun;29(6):462, C3. 119.
Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-­‐‑Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-­‐‑Cass DA. Prostate Cancer, Version 1.2016.J Natl Compr Canc Netw. 2016 Jan;14(1):19-­‐‑30. 120.
Rosenthal DI, Harari PM, Giralt J, Bell D, Raben D, Liu J, Schulten J, Ang KK, Bonner JA. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-­‐‑9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab. J Clin Oncol. 2015 Dec 28. pii: JCO625970. [Epub ahead of print] 121.
Gan GN, Altunbas C, Morton JJ, Eagles J, Backus J, Dzingle W, Raben D, Jimeno A. Radiation dose uncertainty and correction for a mouse orthotopic and xenograft irradiation model. Int J Radiat Biol. 2015 Dec 21:1-­‐‑7. [Epub ahead of print] 122.
Amini A, Rusthoven CG, Jones BL, Armstrong H, Raben D, Kavanagh BD. Survival outcomes of radiotherapy with or without androgen-­‐‑deprivation therapy for patients with intermediate-­‐‑risk prostate cancer using the National Cancer Data Base. Urol Oncol. 2015 Dec 11. pii: S1078 1439(15)00556-­‐‑6. doi: 10.1016/j.urolonc.2015.11.004. [Epub ahead of print] 123.
Amini A, Rusthoven CG, Waxweiler TV, Jones BL, Fisher CM, Karam SD, Raben D. Association of health insurance with outcomes in adults ages 18 to 64 years with melanoma in the United States. J Am Acad Dermatol. 2015 Dec 6. pii: S0190-­‐‑9622(15)02267-­‐‑7. doi: 10.1016/j.jaad.2015.09.054. [Epub ahead of print] Manuscripts Submitted or Under Review Weidhaas JB, Harris J, Rita Axelrod3, El-­‐‑Naggar AK, Singh AK, Galloway TJ, Raben D , Wang D, Herman TS, R. Lee RJ, Manon RR, Yumen O, Bahary JP, Trotti A, Skinner H, Zhang Q and Chung CH. The KRAS-­‐‑variant as a biomarker of favorable cetuximab response in head and neck cancer: NRG Oncology/RTOG 0522 (submitted: Journal of Clinical Oncology) Xiao C, Qiang Zhang Q, Nguyen-­‐‑Tân PF, List M, Weber RS, Ang KK, Rosenthal D, Filion EJ, Kim H, Craig Silverman C, Raben A, Galloway T, Fortin A, Gore E, Robert Veith R, Eric Winquist E, Jones CU, Robinson W, Raben D, Le QT, Deborah Bruner D. Quality of life in a prospective phase III randomized trial of concurrent standard radiation vs. accelerated radiation plus cisplatin for locally advanced head and neck carcinoma: RTOG 0129 (submitted: Journal of Clinical Oncology) McDermott JD, Lu X, Rusthoven CG, Leem T, Song J, Raben D, Jimeno A, Bedrick E, Karam SD, Bowles DW. Survival Impact of Local Therapy for Metastatic Head and Neck Squamous Cell Carcinoma. (Submitted: Journal of Clinical Oncology) Textbook Contributions 1.
Gaspar, L, Mertens W, Raben D, Evans S. Clinical Aspects and Management of Anal Cancer. Oxford University Press, May 2000. 2.
Raben D , Buchsbaum D. Combined External Beam Radiotherapy and Radioimmunotherapy. Targeted Therapy for Cancer. Oxford University Press, London, England, 1999. 3.
Raben D . Treatment of Non-­‐‑Small cell Lung Cancer. Lung Cancer Therapy Annual (3). Martin Dunitz, 2003. 4.
Raben D , Kavanagh B and Raben A. American Cancer Society’s A Complete Guide to Prostate Cancer. Chapter 21: What is External Beam Therapy (EBRT). American Cancer Society, pp. 1 97-­‐‑ 204, 2005. 5.
Sartor C, Raben D . O’Neil, B. Chapter 5: Biologics and Interactions with Radiation. Gunderson L, Tepper J, eds. Clinical Radiation Oncology, 2nd Edition. New York, NY: Churchill Livingstone, 2006. 6.
McCammon R, Chen C, Suntha M, and Raben D. Chapter 92. Chemoradiation for Head and Neck Cancer. 17th Edition of Ballenger's Otorhinolaryngology Head and Neck Surgery. BC Decker Publisher, 2007. 7.
Raben D , Schwer A and Van Houtte P. Targeted Therapies and Radiation in Lung Cancer. Lung Cancer: Principles and Practice, 4th ed. Williams and Wilkins Publisher. 2009 8.
Pugh, TJ, Sartor C, Raben D. Chapter 5: Biologics and Interactions with Radiation. Gunderson L, Tepper J, eds. Clinical Radiation Oncology, 3rd Edition. New York, NY: Churchill Livingstone, 2010. 9.
Raben D , Rusthoven KE: Chapter 5: Combined Modality Therapy in Cancer Management. In: Anticancer Drug Development: Principles and Practices. Hidalgo M, Eckhardt SG, Garrett-­‐‑Mayer E, Clendeninn NJ (eds) 2011 10.
Carlson J, Licitra L, Locati,L, Raben D, Persson F, Stenman G. Salivary Gland Cancer. Am Soc Clin Oncol Educ Book. 2013; 2013:257-­‐‑63. 11.
Waxweiler T, Raben D. Chapter 5: Biologics and Interactions with Radiation. Gunderson L, Tepper J, eds. Clinical Radiation Oncology, 4th Edition. New York, NY: Churchill Livingstone, 2014. Other 1. Patent # 5,902,583, issue date: May 11, 1999: Genetic Induction Of Receptors For Targeted Radiotherapy; Buchsbaum, Curiel, Khazaeli, Raben, et al., USSN 08/739,826; FY96-­‐‑000 Abstracts Presented/Published 1.
Raben D, Kucera LS, Iyer N, Ricardo, MI. Electron Microscopic Evidence for Co-­‐‑Infection and Replication of Herpes Virus and HIV-­‐‑1 in the same Human T-­‐‑cell. 5th International AIDS Meeting; Montreal, Canada. June 1989. 2.
Raben D. Lee J, Lee DJ: Radiotherapy for Nasopharyngeal Carcinoma: An Analysis of Site of Failure. 35th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology; New Orleans, Louisiana. November 1993. 3.
Raben D, Buchsbaum DJ, Khazaeli MB, Rosenfeld ME, Gillespie GY, Curiel D. Adenoviral-­‐‑Mediated Transduction of Genes Encoding for Surface Receptors to Improve Radioligand Tumor Localization. 10th Annual Scientific Meeting of the Society of Biological Therapy; Williamsburg, Virginia. November 1-­‐‑4, 1995. 4.
Raben D, Buchsbaum DJ, Khazaeli MB, Rosenfeld ME, Gillespie GY, Curiel D. Strategies to Augment Radioimmunotherapy Via Genetic Induction of Receptors for Radioligand Binding. Cancer Gene Therapy 2:330, 1995. 5.
Buchsbaum DJ, Rosenfeld ME, Raben D, Khazaeli MB, Liu T, Curiel D T. Genetic Radioimmunotherapy of Cancer. 13th International Hammersmith Conference: Advance in the Applications of Monoclonal Antibodies in Clinical Oncology; Chania, Greece May 27-­‐‑30, 1996. 6.
Vickers SM, Rosenfeld M, Raben D, Sampson LK, Phillips JO, Curiel DT. The In Vitro Application of Molecular Chemotherapy in the Treatment of Pancreatic Cancer. University of Alabama at Birmingham, Birmingham, Alabama. 2nd World Congress of the International Hepato -­‐‑Pancreato-­‐‑ Biliary Association; Bologna, Italy. June 2-­‐‑6, 1996. 7.
Raben D, Buchsbaum DJ, Stackhouse MA, Rosenfeld ME, Mikheeva G, Khazaeli MB, Rogers BE, Curiel RT. Genetic Induction of Novel Receptors in Tumor Cells Enhances Radiolabeled Peptide Targeting. Cold Spring Harbor Laboratory, Cold Spring Harbor; NY, New York. September 25-­‐‑29, 1996. 8.
Hixon WC, Raben D, Jaffe KA, Salter MA. Accelerated Interstitial High Dose Rate Brachytherapy as a Boost Technique in the Treatment of Soft Tissue Sarcomas. 38th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology; LA, California. October 27-­‐‑30, 1996. 9.
Raben D, Stackhouse M, Buchsbaum DJ, Mikheeva G, Khazaeli MB, McLean S, Kirkman R, Krasnykh V, Curiel DT. Genetic Induction of the Gastrin Releasing Peptide Receptor on Tumor Cells for Radiolabeled Peptide Binding. International Journal Radiation Oncology Biol. Physics; 36(suppl 1):378, 1996. 10.
Meyer JT, Hixson WC, Jennelle RLS, Alonso JE, Raben D, Spencer SS, Kim RY. Prophylactic P ost-­‐‑ Operative Radiotherapy Prevents Heterotopic Ossification Following Traumatic Cetabular Fracture. 38th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology; Los Angeles, California. October 27-­‐‑30, 1996. 11.
Raben D. Buchsbaum DJ, Mikheeva G, Grizzle WE, Khazaeli MD, Rogers B, Curiel DT, Garver RI, Jr. A to Augment Efficacy of Genetic Radiation Immunotherapy by use of Conditionally Replication-­‐‑ Enabled Adenovirus. Cancer Gene Therapy 3:531, 1996. 12.
Pederson LC, Vickers SM, Buchsbaum DJ, Raben D, Kancharla R, Curiel DT, Stackhouse MA. Molecular Chemotherapy Combined with Radiation Therapy Enhances Killing of Cholangiocarcinoma. Gastroenterol 112:A 1464, 1997. 13.
Buchsbaum DJ, Rogers BE, Raben D, McLean S, Laffoon K, Myracle A, Grimes C, Carpenter T, Bright S, Olsen C, Curiel DT. Genetic Induction of Somatostatin Receptor in Tumor Cells Enhances Binding and Localization of Radiolabeled Octreotide; XII International Symposium on Radiopharmaceutical Chemistry; Uppsala, Sweden. June 15-­‐‑19, 1997. 14.
Miller R, Rogers BE, Carpenter T, Douglas JT, Gillespie GY, Buchsbaum DJ, Curiel DT, Raben D. Improved Radiolabeled Peptide Localization to Gliomas through the use of Targeted Adenoviral Vectors. Cancer Gene Therapy 4:S30-­‐‑S31, 1997. 15.
Miller CR, Rogers BE, Carpenter T, Douglas J T, Gillespie GY, Raben D, Wells A, Buchsbaum DJ, Curiel DT. EGFR Targeted Adenovirus Gene Delivery. Keystone Conferences: The Molecular and Cellular Biology of Gene Therapy; Keystone, Colorado. January 19-­‐‑25, 1998. 16.
Miller CR, Rogers BE, Douglas JT, Gillespie GY, Raben D, Buchsbaum DJ, Curiel DT. EGFR Targeted Adenoviral Mediated Gene Delivery to Human Glioblastoma Tumors. 89th Annual Meeting, Proceedings of the American Association of Cancer Research for AACR; New Orleans, Louisiana. March 28 – April 1, 1998. 17.
Miller CR, Buchsbaum DJ, Carpenter T, Douglas J, Gillespie GY, Curiel DT, Raben D. Retargeting of Adenovirus to the Epidermal Growth Factor Receptor Results in Efficient Gene Delivery to Cultured and Primary Human Glioma Cells. 1st Annual Meeting, American Society of Gene Therapy; Seattle, Washington. May 28-­‐‑31, 1998. 18.
Buchsbaum DJ, Roger BE, Raben D, Garver Jr. RJ, Grizzle WE, Khazael MB, Curiel DT. Genetic Radioisotope Targeting Strategies for Cancer Localization and Therapy. 1st Annual M eeting, American Society of Gene Therapy; Seattle, Washington. May 28-­‐‑31, 1998. 19.
Urban D, Bueschen A, Kim R, Raben D, Pettus J. Iodine 125 Brachytherapy, A Minimally Invasive Treatment for Localized Prostate Cancer: Preliminary Report. Journal of Endourology; 12(suppl 1), 16th World Congress on Endourology. New York, NY, September 3 -­‐‑6, 1998. 20.
Raben D, Buchsbaum D, Gillespie G, Saleh M, Waksal H. Enhanced Survival of Nude Mice Bearing Human Gliomas Treated with Concurrent Unlabeled Anti-­‐‑epidermal Growth Factor Receptor (Anti-­‐‑EGFr) Antibody and Irradiation. American Radium Society, Annual Meeting, Hawaii, April 17-­‐‑21, 1999. 21.
Raben D, Buchsbaum D, Gillespie G, Saleh M, Waksal H. Treatment of Human Intracranial Gliomas with Chimeric Monoclonal Antibody against the Epidermal Growth Factor Receptor Increases Survival of Nude Mice when treated Concurrently with Irradiation. 90th Annual Meeting, Procedings of the American Association of Cancer Research. Philadelphia, PA, April 10-­‐‑14, 1999. 22.
Kim Ry, Ezekiel MD, Zinsil T, Raben D, Bueschen AJ, Urban MD. Use of CT Based 3 -­‐‑D Images of the Pelvis to Circumvent Public Arch Interference during Transperineal Prostate Implantation. Radiology 209, 1998. 23.
Soriano A, Helfrich S, Holden S, Chan D, Raben D, Bunn P. Synergistic Effects of Chemotherapy (CT) or Radiation (RT) and Herceptin against Human Non-­‐‑Small Cell Lung Cancer (NSCL) Expressing the HER-­‐‑2/new Receptor. 12th International Conference on Monoclonal Antibodies for Cancer, San Diego, CA. October 14-­‐‑16, 1999. 24.
Spencer SA, Childs HA, Tincher SA, Raben D, Bonner JA, Robert F. Final Results of a Phase I Study of Combined UFT Plus Leucovorin and Radiation Therapy for Pancreatic Cancer. 41st Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology. San Antonio, Texas. October 31, 1999. 25.
Bunn P, Soriano A, Helfrich B, Raben D, Holden S, Chan D, Garcia M. HER2/neu Expression and Effects of Herceptin alone and in Combination with Cytotoxic Agents in Lung Cancer. 91st Annual Meeting, Procedings of the American Association of Cancer Research. San Francisco, California, April 1-­‐‑5, 2000. 26.
Batuello JT, Gamito EJ, Crawford D., Partin AW, McLeod R, Stock R, Stone S, Raben D. Artificial Neural Network to Predict Risk of Lymph Node Spread in Men with Clinically Localized Prostate Cancer and Method to Improve Utility of ANN Output. 36th Annual Meeting, Procedings of the American Society of Clinical Oncology, New Orleans, Louisiana, May 20-­‐‑23, 2000. 27.
Raben D, Helfrich B, Phistry M, Chan D, Bunn P. ZD1839 (Iressa), an EGFR-­‐‑TKI Potentiates Radiation/Chemotherapy Cytotoxicity in Human Non-­‐‑Small Cell Lung Cancer Cell Lines (NSCLC), 11th AACR-­‐‑NCI-­‐‑EORTC Special Conference in Cancer Research, Amsterdam, November 6-­‐‑11, 2000. 28.
Raben D, Phistry M, Helfrich B, Chan D, Bunn P. ZD1839 (Iressa), A Selective Epidermal Growth Factor (EGFR)-­‐‑Tyrosine Kinase Inhibitor (TKI), Appears to Enhance Radiation (RT) Induced Cytotoxicity in Human Pancreatic and Cholangiocarcinoma Cell Lines in Vitro, 1st Annual MDACC Gastrointestinal Cancer Conference, Orlando, FL, November 16-­‐‑18, 2000. 29.
Helfrich B, Phistry M, Chan D, Oliver T, Bunn P, Raben D. ZD1839 (Iressa), A Selective EGFR-­‐‑TKI Enhances Radiation and Chemotherapy Cytotoxicity in EGFR Positive Human Non-­‐‑Small Cell Lung Cancer Cells (NSCLC) In Vitro. AACR, Maui, Hawaii, February 12-­‐‑16, 2001. 30.
Raben D, Helfrich B, Chan D, Phistry M, Kee A, Zhao T, Zundel W, Bunn P. C225 Anti-­‐‑EGFR Antibody Potentiates Radiation (RT) and Chemotherapy (CT) Cytotoxicity in Human Non-­‐‑Small Cell Lung Cancer (NSCLS) Cells in Vitro and In Vivo, 37th Annual Meeting, Proceedings of the American Society of Clinical Oncology, San Francisco, CA, May 12-­‐‑15, 2001. 31.
Raben A, Grebler A, Ivker R, Geltzeiler J, Yang J, Shoengold S, Helfman A, Raben D, Baron A, Zeng C, Coia L. Patterns and Predictors of Acute Toxicity after HDR Brachytherapy and 3D-­‐‑CRT for Localized Prostate Cancer: Preliminary Results of Phase I-­‐‑II Dose Escalation Study, Annual Meeting of the American Brachytherapy Society, Vancouver, Canada, May 19-­‐‑22, 2001. 32.
Gamito E, Crawford D, O’Donnell C, Han M, Partin A, Tewari A, Errejon A, Raben D. Artificial Neural Network Model to Predict Risk of Non-­‐‑Organ-­‐‑Confined Disease and Risk of Lymph Node Spread in Men with Clinically Localized Prostate Cancer. Proceedings of the American Society of Clinical Oncology, 37th Annual Meeting, San Francisco, CA, May 12-­‐‑15, 2001. 33.
Raben D, Helfrich B, Chan D, Shogun T, Zundel W, Sclafani R, and Bunn PA. The Effects of ZD1839 on Cell Signaling Processes and its Growth Effects With Radiation and Chemotherapy in Human Non-­‐‑Small Cell Lung Cancer Cells in Vitro. 12th AACR-­‐‑NCI-­‐‑EORTC Special Conference in Cancer Research, Oct. 29-­‐‑Nov.2, Miami Beach, FL, 2001. 34.
Helfrich B, Raben D, Chan D, Garcia L, Shogun T, Zundel W, Hirsch F, Franklin W, Bunn P. C225 anti-­‐‑epidermal growth factor receptor (EGFR) monoclonal antibody sensitizes human non-­‐‑small cell lung cancer to both radiation and chemotherapy cytotoxicity in-­‐‑vitro and in-­‐‑vivo. ASTRO 43rd Annual Meeting, San Francisco, CA, November 4-­‐‑8, 2001 35.
Raben D, Chan D, Franklin W, Helfrich B, Garcia M, Bunn PA. Effect of EGF receptor inhibitors alone and in combination with chemotherapy and radiotherapy on the growth of human lung cancer cell lines. Proceedings of the SPORE Meeting, July 15-­‐‑17, Washington, DC, 2002. 36.
Eldridge B, Rabinovitch R, Berkey B, Raben D, Ang KK, Fu K. The Impact of Baseline Nutritional Support on Treatment Outcome in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck Treated with Definitive Radiotherapy: Report of the Radiation Therapy Oncology Group (RTOG) Trial 90-­‐‑03. Proceedings of the 44th American Society Therapeutic Radiation Oncologists (ASTRO), Int J. Radiat Oncol Biol Phys, (Abs.) October 4 -­‐‑8, New Orleans LA, 2002. 37.
Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, Paolo F, D’Armiento, Bianco AR, Tortora G, and Ciardiello F. ZD6126, a Novel Vascular Targeting Agent, Strongly Enhances the Effects of Ionizing Radiation (RT) and ZD1839 (Iressa) in Human Non-­‐‑Small Cell Lung Cancer (NSCLC). Proceedings from 1st International Symposium on Signal Transduction Modulators in Cancer Therapy. Amsterdam, September 23-­‐‑25, 2002. 38.
Raben D, Chan D, Helfrich B, Franklin W and Bunn PA. EGFR inhibition with ZD1839 (‘Iressa’) augments radiation therapy in non-­‐‑small cell lung cancer (NSCLC): translation from pre-­‐‑clinical to clinical investigations. ASCO Molecular Targets Meeting, San Diego CA, Nov. 8 -­‐‑11, 2002. 39.
Raben D. The Emerging Role of EGFR and COX-­‐‑2 Inhibitors in the Treatment of Human Cancers: Walk Before You Run! 12th International Conference of Radiation Research, Brisbane, Australia, August 18, 2003. 40.
Raben D, Weng E, Kane M, et al. Preliminary report on toxicity of a phase I trial of gefitinib (IressaTM) in combination with radiation/chemotherapy for patients with locally advanced head and neck cancer (LAHNC). AACR-­‐‑NCI-­‐‑EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, Nov. 17-­‐‑21, 2003. 41.
Raben A, Grebler A, Sim S, Geitzeller J, Keselman I, Litvin S, Geitzeller M, Raben D, Crawford D, and Yang J. Analysis of acute and late morbidity and biochemical control for intermediate to high risk prostate cancer treated with androgen deprivation, HDR and 3D/IMRT: a 4 year results of a phase I-­‐‑II dose escalation trial. International Brachytherapy Meeting, Barcelona, Spain. Radiotherapy Oncology GEC-­‐‑ESTRO, Vol 71(suppl 2) May 15, 2004. Abst #105 (oral). 42.
Bonner J, Harari P, Giralt J, Azarnia N, Cohen R, Jones C, Sur RK, Raben D, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. Proceedings of the American Society of Clinical Oncology, 40th Annual Meeting, New Orleans, LA 2004. Abst # 5507 (LBA). 43.
Raben D, Kane M, Chen C, Song J, et al. Update on the toxicity and response of a phase I trial of concurrent, daily gefitinib and radiation or chemo-­‐‑radiation for patients with locally advanced squamous cell cancer of the head and neck (LASCCHN). 16th EORTC-­‐‑NCI-­‐‑AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, September 28, European Journal of Cancer (Supp) Vol. 2(8), 2004. 44.
Bonner J, Harari P, Giralt J, Azarnia N, Cohen R, Jones C, Sur RK, Raben D, et al. A phase III study of radiation with or without cetuximab in local-­‐‑regionally advanced head and neck cancer. Proceedings of the 46th Annual Scientific Meeting of the American Society Therapeutic Radiation Oncologists (ASTRO), Atlanta GA, Oct 3-­‐‑8, 2004, Int J Radiat Oncol Biol Phys., Supp. 60(1), Abst # 31 S147. 45.
Frederick B, Helfrich B and Raben D. Is Hypoxia Relevant in Modulating the Effects of ZD6474, An Active Dual EGFR-­‐‑VEGFR Tyrosine Kinase Inhibitor, in Head and Neck Cancer? 16th EORTC-­‐‑NCI-­‐‑ AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, September 28, European Journal of Cancer (Supp) Vol. 2(8), 2004. Helfrich B, Troiani T, Raben D, Frederick B, et al. Anticancer effects of ZD6474 in gefitinib (IressaTM)-­‐‑resistant lung cancer cell lines in vitro. 16th EORTC-­‐‑NCI-­‐‑AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, September 28, European Journal of Cancer (Supp) Vol. 2(8), pp51, 2004. 46.
47.
Gustafson D, Merz A, Zirrolli J, Raben D. Impact of Scheduling on Combined VEGFR/EGFR Tyrosine Kinase Inhibition by ZD6474 and Radiotherapy in Human Head and Neck Tumor Xenografts. 16th EORTC-­‐‑NCI-­‐‑AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, September 28, European Journal of Cancer (Supp) Vol. 2(8), 2004. 48.
Raben D, Gustafson D, Frederick B, et al. Anti-­‐‑tumor efficacy of ZD6474, a VEGFR tyrosine kinase inhibitor with additional activity against EGFR tyrosine kinase, alone and in combination with radiotherapy in human head and neck cancer. Abstracts of the 3rd International Chicago Symposium on Malignancies of the Chest and Head and Neck, Chicago, Ill, Lung Cancer 46: Suppl. 1, Abs. S24, Oct. 7-­‐‑9, 2004. 49.
Bianco C, Giovanetti E, Danesi R, Ciardiello F, Mey V, Tortora G, Gambardella U, Pasqualetti F, Nannizzi S, Cionini L, Raben D, Del Tacca M. Enhancement of cytotoxic activity of gemcitibine and ionizing radiation by combined treatment with the VEGF and EGF receptor tyrosine kinase inhibitor ZD6474 against pancreatic cancer cells in vitro. 96th Annual Meeting of the AACR, April 16-­‐‑20, Anaheim, CA, 2005, PO.TB34. Radiation Biology 3, Abst # 4752. 50.
B.A. Murphy, B. Shaktour, D. Raben, W. Reid, J. Netterville, B. Burkey, B. Kish, J. Song, M. Kane, A.J. Cmelak A Phase II Multi-­‐‑Institutional Trial of Chemoradiation (CR) Using Weekly Docetaxel (Doc) and Erythropoetin (Epo) for High-­‐‑Risk Postoperative Head and Neck Cancer (HRHNC) Patients. Proceedings of the American Society of Clinical Oncology, 41st Annual Meeting, May 13-­‐‑ 17, Orlando FL, 2005, Vol 23. No16S, Abstract # 5591. 51.
Raben D, Chen C, Eckhardt GS, Kane M, Song J, Bemis L, Varella-­‐‑Garcia, M, Brualdi L, Hu K, Quon H, and Dancey J. Maturing toxicity and outcomes of a phase I trial of concurrent daily gefitinib and radiation or chemo-­‐‑radiation for patients with locally advanced squamous cell carcinoma of the head and neck. Proceedings of the 47th Annual Scientific Meeting of the American Society Therapeutic Radiation Oncologists (ASTRO), Denver, CO, Oct 16-­‐‑20, 2005, Int J Radiat Oncol Biol Phys., Supp. 60(1), Abstract # 2237. 52.
Rothschild B, Frederick B, Helfrich B, Weed S, Shim A, Song J and Raben D. Combining the Src Inhibitor, AZD0530, with Ionizing Radiation Yields Additive Effects Without Modulation of Phospho-­‐‑Sites on Src, EGFR or MAPK. For poster presentation at AACR-­‐‑NCI-­‐‑EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, Philadelphia, PA, Nov14-­‐‑18th, 2006. 53.
Chen H, Raben D, et al. KRAS Mutation Analysis in Patients with Locally Advanced Pancreatic Cancer (LAPC) Treated with Gefitinib and Chemoradiation Therapy (CT-­‐‑PCR) in Phase I Trial. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part II. Vol 24, No. 18S (June 20 Supplement), 2006: #4106. 54.
Chen C, Damek D, Lillihei K, Raben D, et al. A Phase I dose escalation study of hypofractionated stereotactic radiotherapy in combination with ZD1839 (Iressa TM) in patients with recurrent malignant gliomas. Proceedings of the 48th Annual Scientific Meeting of the American Society Therapeutic Radiation Oncologists (ASTRO), Philadelphia, PA, Nov 5 -­‐‑9, 2006. Int J Radiat Oncol Biol Phys., Supp. 66(3), Abstract # 1120. 55.
McCammon R, Kavanagh B, Raben D, et al. Acute toxicity assessment of a single institution series of prostate cancer patients treated with pelvic intensity modulated radiation therapy with synchronous integrated boost to the prostate or prostate bed. Proceedings of the 48th Annual Scientific Meeting of the American Society Therapeutic Radiation Oncologists (ASTRO), Philadelphia, PA, Nov 5-­‐‑9, 2006. Int J Radiat Oncol Biol Phys., Supp. 66(3), Abstract # 2277. 56.
Olsen C, Kavanagh B, Raben D, et al. Stereotactic body radiation therapy (SBRT) vs high dose rate brachytherapy (HDR) as hypofractyionated radiation therapy for prostate cancer: a comparison of achievable tumor and normal tissue doses. Proceedings of the 48th Annual Scientific Meeting of the American Society Therapeutic Radiation Oncologists (ASTRO), Philadelphia, PA, Nov 5-­‐‑9, 2006. Int J Radiat Oncol Biol Phys., Supp. 66(3), Abstract # 2310. 57.
Bianco C, Giovanetti E, Ciardiello F, Mey V, Nanizzi S, Pasqualetti F, Troiani T, Raben D, et al. Synergistic antitumor activity of ZD6474, an inhibitor of VEGFR and EGFR signaling, w ith gemcitabine and ionizing radiation against pancreatic cancer. Proceedings of the 48th Annual Scientific Meeting of the American Society Therapeutic Radiation Oncologists (ASTRO), Philadelphia, PA, Nov 5-­‐‑9, 2006. Int J Radiat Oncol Biol Phys., Supp. 66(3), Abstract # 2162. 58.
Bonner, JA, Giralt J, Harari PM, Cohen R, Jones C, Sur RK, Raben D, et al. Prolongation of survival with the addition of cetuximab to radiation in patients with locoregionally advanced head and neck cancer (SCCHN): Five-­‐‑year results from a randomized trial. American Society for Therapeutic Radiology and Oncology 2008 Annual Meeting Late breaking Abstracts Int J Radiat Oncol Biol Phys. 1 September 2008 (Vol. 72, Issue 1, Pages e1-­‐‑e4, DOI: 10.1016/S0360-­‐‑ 3016(08)03646-­‐‑8) (LB3). 59.
Lopez-­‐‑Skinner L, Kelley L, Gatesman-­‐‑Ammer A, Rothschild B, Frederick B, Raben D, Green T, Flynn D and Weed West S. The novel Src/Abl kinase inhibitor AZD0530 inhitbits proliferation, invasion and invadopodia formation in head and neck squamous cell carcinoma. Proceedings of the100th AACR Meeting, Denver, CO. Apr 18-­‐‑22, 2009. Abstract #3247 60.
Amanda Gatesman Ammer, Laura C. Kelley, Karen E. Hayes, Jason V. Evans, Lesly Ann L opez-­‐‑ Skinner, Karen H. Martin, Brian L. Rothschild, Barbara Frederick, David Raben, Tim P. Green, Scott A. Weed. West Virginia Univ. Health Sciences Ctr., Morgantown, WV, University of Colorado Denver, Aurora, CO, AstraZeneca Phamaceuticals, Cheshire, United Kingdom. The Src inhibitor AZD0530 suppresses head and neck squamous cell carcinoma invasion by disrupting invadopodia activity. Proceedings of the100th AACR Meeting, Denver, CO. Apr 18-­‐‑22, 2009. Abstract #3772 61.
Sclafani R, Siriwardana S, Frederick B, Stahringer S, Tyagi A, Jimeno A, Agarwal A, Raben D. Combined Resveratrol and radiation therapy in head and neck cancer. Abstract #University of Colorado Denver School of Medicine. Aurora, CO. University of Colorado School of Pharmacy, Aurora, CO. Proceedings of the100th AACR Meeting, Denver, CO. Apr 18-­‐‑22, 2009Abstract #3989 62.
Barbara Frederick, Barbara Helfrich, Ashley Fletcher, David Raben. University of Colorado Denver, Aurora, CO. The Src inhibitor AZD0530 induces autophagy in head and neck squamous cell carcinoma and non-­‐‑small cell lung cancer cell lines. Proceedings of the 100th AACR Meeting, Denver, CO April 18-­‐‑22, 2009#392 63.
Aik Choon Tan, Ryan Anderson, Barbara Frederick, David Raben, Antonio Jimeno. University of Colorado Denver, Aurora, CO. Pathway-­‐‑based comparison approach for the identification of responders to the mitotic modulator ON 01910.Na in head and neck cancer (HNC) Proceedings of the100th AACR Meeting, Denver, CO. Apr 18-­‐‑22, 2009Abstract #4702 64.
Marianne E. Marshall, Scott A. Kono, Brady Bichon, Linsday A. Marek, Barbara A. Frederick, David Raben, Lynn E. Heasley. Univ. of Colorado, Aurora, CO 5232 Autocrine signaling by FGFs and FGFRs in HNSCC cells Proceedings of the100th AACR Meeting, Denver, CO. Apr 18-­‐‑22, 2009Abstract #5232 65.
Ian J. Stratford, Brian` Telfer, Tim P. Green, Paul Elvin, Anderson Ryan, David Raben, Stephen R . Wedge. Univ. of Manchester School of Pharmacy, Manchester, United Kingdom, Cancer Bioscience, AstraZeneca, United Kingdom, University of Colorado Denver, Aurora, CO. Inhibition of metastatic dissemination following loco-­‐‑regional control of a primary tumor: examining a novel treatment paradigm with the Src kinase inhibitor AZD0530. Proceedings of the100th AACR Meeting, Denver, CO. Apr 18-­‐‑22, 2009Abstract #4946 66.
Impact of Correcting Anatomic Distortions on Daily Delivered Doses in Post-­‐‑Prostatectomy Patients M. Miften, Q. Diot, L. Gaspar, D. Raben, J. Martinez, T. Schuchman, B. Kavanagh Department of Radiation Oncology, University of Colorado Denver, Aurora, CO 67.
Metabolic Tumor Volume and Oropharynx Subsite as Prognostic Factors in Advanced Head and Neck Cancer. D. Raben, C. Chen, B. Loo, E. Graves, B. Kavanagh, University of Colorado Cancer Center, Aurora, CO, Stanford University, Palo Alto, CA Abstract #2124 68.
The PARP1 inhibitor olaparib (AZD2281) enhances radiation-­‐‑induced DNA damage in BRCA1/BRCA2 wild-­‐‑type head and neck squamous cell carcinoma cell lines. Frederick B, Fletcher A, Raben D. University of Colorado Denver, Aurora CO. M ol Cancer Ther 2009;8(12 Suppl):A118. 69.
Preliminary Outcomes for Treatment of High Intermediate-­‐‑and High Risk Prostate Cancer Patients using Pelvic Intensity-­‐‑Modulated Radiotherapy with Hypofractionated Simulataneous Integrated Boost to Prostate. Reddy K, Nelson BC, McCammon R, Rusthoven KE, Newman F, Kavanagh B, Raben D. University of Colorado Denver, Aurora CO. Abstract #570. 70.
Phase I Trial of Concurrent Bortezomib, Paclitaxel, and External Beam Radiation in Patients with Unresectable Pancreatic or Billiary Cancer. Pugh TJ, Schefter TE, Kane M, Eckhardt SG, McCarter M, Chen YK, Swing R, Draheim L, Raben D. University of Colorado Denver, Aurora CO. Abstract#2538 71.
Stereotactic Body Radiation Therapy for Melanoma and Renal Cell Carcinoma: Impact of Single Fraction Equivalent Dose of Local Control. Stinauer M, Kavanagh B, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D. University of Colorado Denver, Aurora CO. Abstract#569. 72.
The Role of Health Locus of Control in the Continued use of Alcohol and Tobacco in Head and Neck Cancer Survivors. Shih S, Madore A, Bevan A, Costenaro A, Anderson D, Raben D, A llen J, Kilbourn K. The Ohio State University, Columbus OH, University of Colorado Denver, Aurora CO. Abstract#0175. Active or Recently Completed Protocols 1.
NCI-­‐‑CTEP sponsored multi-­‐‑institutional Phase I/II study of Iressa, radiation and cisplatin for patients with locally advanced head and neck cancer. (accrual completed). Principal Radiation Oncology Investigator: David Raben, M.D. 2.
Millennium Pharmaceuticals sponsored Phase I study of Bortezomib and concurrent radiation in patients with advanced malignancies (currently accruing). Principal Radiation Oncology Investigator: David Raben, M.D. 2.
Astra-­‐‑Zeneca sponsored Phase II randomized, double blind, placebo controlled, multicenter comparative study of ZD1839 250 mg or 500 mg (IressaTM) given either continuously or concomitantly with cisplatin plus radiotherapy for the treatment of patients with previously untreated unresected late stage III/IV non-­‐‑metastatic head and neck squamous cell carcinoma. (accrual completed). Principal Radiation Oncology Investigator: David Raben, M.D. 3.
Astra-­‐‑Zeneca sponsored single institution phase I/II study of Iressa in combination with paclitaxel and radiation in patients with locally advanced, unresectable carcinoma of the pancreas. (accrual completed) Principal Radiation Oncology Investigator: David Raben, M.D. 4.
AstraZeneca sponsored Multi-­‐‑Center Phase I/II study of Iressa in Combination With External Beam Radiation and Chemotherapy With Consolidation Carboplatin/Paclitaxel Followed By Maintenance Iressa in Untreated Patients With Locally Advanced (Stage III), Non-­‐‑Small Cell Lung Cancer (NSCLC). (closed early due to poor accrual) Principal Radiation Oncology Investigator: David Raben, M.D. 5.
Millennium Pharmaceuticals sponsored Phase I study of Bortezomib and concurrent radiation/paclitaxel in patients with locally advanced pancreatic carcinoma or cholangiocarcinoma. (closed to accrual) Principal Radiation Oncology Investigator: David Raben, M.D. 6.
Phase I/II study of erlotinib (TarcevaTM) with conformal 3 -­‐‑D re-­‐‑irradiation in patients with locally recurrent squamous cell cancer of the head and neck (completed) Co-­‐‑Principal Radiation Oncology Investigator: David Raben, M.D 7.
AstraZeneca sponsored multi-­‐‑institutional phase I/II trial combining ZD6474, a dual EGFR-­‐‑ VEGFR tyrosine kinase inhibitor, in combination with radiotherapy or chemo-­‐‑radiotherapy for patients with locally advanced, unresectable stage III/IV squamous cell cancer of the head and neck. (Accrual completed) Principal Radiation Oncology Investigator: David Raben, M.D. 8.
RTOG 0619: A Phase I /II trial of induction ZD6474 followed by surgery followed by chemoradiation plus ZD6474 for high risk postoperative advanced squamous cell carcinoma of the head and neck. (closed to accrual) Principal Radiation Oncology Investigator: David Raben, M.D. 9.
Phase I trial of Olaparib, an Oral PARP inhibitor with Radiation after Induction TPF for Patients with Locally Advanced, HPV Negative Head and Neck Cancer. Principal Radiation Oncology Investigator: David Raben, M.D. Currently accruing Administrative Responsibilities International Medical Committee Responsibilities: Assist in building international outreach medical services, collaborations for research and clinical treatment of patients with locally advanced cancers